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Introduction

Introduction 11
Hepatitis B virus
The hepatitis B virus (HBV) is a 42 nm viral particle and belongs to a family of closely related DNA 
viruses called the hepadnaviruses [1-2]. All the hepadnaviruses have similar hepatotropism and 
life cycles in their hosts [3]. It is an enveloped small circular, partially double stranded DNA 
virus.
The viral genome has a length of approximately 3200 base pairs that encodes four open 
reading frames (ORF). These are the pre-Surface (pre-S) and Surface (S) gene, the pre-Core 
(pre-C) and Core (C) gene, the X-gene and the Polymerase (P)-gene. The pre-S and pre-C 
genes are upstream regions of the S and C genes [2]. The viral envelope encoded by the S 
gene contains three distinct configurations synthesized in all infected persons, termed the 
large, middle and major envelope proteins, which are produced by beginning transcription 
at, respectively, the pre-S1, pre-S2 or the S gene. The pre-S1 and pre-S2 represent two of the 
more immunogenic portions of hepatitis B surface antigen (HBsAg) [4]. The development of 
cellular and humoral immunity to HBsAg is protective [5], and recombinant HBsAg provides 
the basis for the HBV vaccines currently available. The hepatitis B core antigen (HBcAg) is the 
nucleocapsid that encloses the viral DNA. When HBcAg-derived peptides are presented by 
MHC-molecules present on the surface of hepatocytes, they can initiate a cellular immune 
response that is important for viral clearance [6].
A signal sequence in the pre-C region of the genome is thought to guide the HBcAg precursor 
to the endoplasmic reticulum of the hepatocyte, where the hepatitis e antigen (HBeAg) 
polypeptide is produced by cleavage of the p25 precursor in its basic C-terminal region. 
Subsequently, it is exported from the liver and serves as marker of active viral replication [7]. 
HBeAg may act as a tolerogen, since its presence in the circulation has been associated with a 
diminished cellular immune response. This may be due to its close resemblance to HBcAg, the 
main target of the immune response [8-10]. 
The longest open reading frame of the HBV genome is the P-gene, which overlaps the other 
genes. The P-gene encodes the HBV DNA polymerase, which also serves a reverse-transcriptase 
function, since replication requires RNA intermediates.
The X-gene is the smallest HBV open reading frame and encodes two proteins that serve as 
transcriptional transactivators, enhancing the transcription as well as the replication of HBV. 
Hepatocytes are the primary replication site for HBV. Following receptor binding of HBV 
particles, the virions enter the hepatocyte and deliver their nucleocapsids to the cytoplasm. 
These then translocate to the nucleus of the hepatocyte, where the virus DNA is repaired and 
converted to covalent closed circular DNA (cccDNA). Host RNA polymerase then transcribes 
the cccDNA, and the resulting RNA’s are translated. Viral pregenomic RNA’s are packaged in 
the cytoplasm into core particles with one HBV polymerase protein. Within this complex DNA 
synthesis is started: a minus DNA strand will be formed and subsequently the plus strand is 
synthesized. Small, middle and large HBsAg transcripts are transported to the endoplasmic 
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reticulum to envelop the core particles. The enveloped virions are subsequently secreted via 
the vesicular transport system into serum. 
Hepatitis C virus
The genetically complex hepatitis C virus (HCV) is an RNA-virus, and has recently been classified 
as a Hepacivirus of the Flaviviridae family [11-12]. It is approximately 50 nm in diameter and 
the 9.6 kb single-stranded, positive sense RNA genome encodes a single polyprotein of about 
3010 aminoacids in length, which is processed by proteases into structural (S; at least three) and 
nonstructural (NS) (six) proteins.
HCV is classified into 6 major genotypes and several subtypes [13], having possible 
significance in both the route of transmission and the histological activity of viral hepatitis [14-
15]. A specific characteristic of the HCV is the high variability of its nucleotide sequence. The 
viral RNA-dependent RNA polymerase is mainly responsible for this inaccuracy, which leads to 
formation of quasispecies [12]. 
HCV attaches to the cell surface of hepatocytes mainly binding of HCV envelope protein E2 to 
CD81 expressed on hepatocytes, which is a putative HCV receptor that belongs to the tetraspanin 
family [16]. Attachment is followed by entry into the cell. HCV replicates in the cytoplasm of the 
hepatocytes. The virus is uncoated, exposing the positive-strand RNA genome. 
After translation, a single large polyprotein is produced, which is to be cleaved into S and NS 
proteins. The positive–strand serves as a template for generating a negative-strand RNA, which 
after binding to the NS proteins forms a replicating complex producing further positive-strand 
RNA. Subsequently, final viral assembly occurs in the Golgi-cisternae with a covering by a lipid 
envelope followed by secretion [17].
Figure 1. HBV replication in hepatocyte
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Immunopathogenesis of chronic hepatitis B and C
HBV and HCV are the two major causes of chronic liver inflammation wordwide [18, 19]. Both 
viruses are preferentially hepatotrophic, but not directly cytopathic. Aproximately 5 to 10 % of 
adults infected by HBV develop a chronic infection, whereas more than 70 % of patients become 
persistently infected with HCV. Chronic hepatitis B and C virus infection is a serious clinical 
problem because of its global distribution and serious complications [20, 21]. It is defined as 
persistence of HBV or HCV replication for more than 6 months after the initial acute infection. 
Inoculation with the virus causes hepatocellular inflammation and necrosis which ranges in 
severity from asymptomatic infection to severe symptomatic infection with progressive or even 
fatal illness. In patients who develop a chronic hepatitis B or C there is an increased risk of liver 
cirrhosis, portal hypertension and hepatocelluar carcinoma [22-23]. 
The T-cell response against HBV and HCV
It is still not clear why certain patients develop a chronic hepatitis B or C infection, while 
others clear these viruses after an acute infection. The inability to mount an efficient T-helper 
and cytotoxic T-cell responses against the virus is thought to play a key role in the course and 
outcome of hepatitis B or C in terms of liver damage and viral control resulting into chronicity. 
In patients with self-limited HBV-infection, the CD8+ cytotoxic response to viral antigens is 
strong and multispecific, whereas this response is weak or undetectable in chronically infected 
patients [24-30], except during acute exacerbations or interferon alpha-induced viral clearance 
[31, 32]. 
Despite a strong T-cell response to HBV during acute viral hepatitis very low levels of virus 
remain present in the circulation for several decades following complete resolution of disease 
[33]. In addition, HBV-specific cytotoxic T-lymphocytes (CTLs) remain present in the circulation 
Figure 2. HCV replication in hepatocyte
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suggesting that after clinical recovery equilibrium between HBV and the host immune system 
is established [34].
In contrast, chronically HCV infected patients do mount a polyclonal and multispecific CTL 
response to several HCV-encoded proteins [35-39], but probably not strong enough qualitatively 
and quantitatively. The establishment of a chronic HCV infection leads to a lower number of 
circulating and intrahepatic virus-specific CD8+ and CD4+ T-cell [40, 41] and to a defective CD8 
T-cell function [42], which is probably maintained by the prolonged exposure to viral antigens 
or immunosuppression, by viral gene products [43, 44]. 
It is thought that liver damage is the direct consequence of lysis of infected hepatocytes, 
mediated by a cellular response to epitopes of HBV and HCV proteins, presented on the surface 
on the hepatocyte. HLA class I restricted CD8 T-cells recognize HBV or HCV peptide fragments 
derived from intracellular processing and presented on the hepatocyte surface by class I 
molecules. 
This process leads to direct hepatocyte killing by the CD8 CTL, probably mediated by Fas 
Ligand- and/or perforin/granzyme-, pathways, resulting in apoptosis. However, recent studies 
suggest that CTLs may inhibit viral replication and inactivate HBV without killing the infected 
hepatocyte. In an HBV transgenic mouse model it has been clearly shown that HBV replication 
is completely abolished in the hepatocytes by secretion of the antiviral cytokines IFN gamma 
and TNF alpha by CTL [45-47]. 
Figure 3. A cytotoxic T-lymphocyte (CTL), by way of its TCR and CD8, can bind to MHC-I epitope on a virus-infected and cause 
apoptosis by way of perforins and granzymes. In addition, a Fas ligand (FasL) on the CTL can bind to a Fas molecule on the 
virus-infected cell and activate the enzymes that lead to apoptosis of the infected cell by means of destruction of its structural 
cytoskeleton proteins and by chromosomal degradation. 
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It has been postulated that the HBV and HCV specific immune response is too weak to eliminate 
the virus from all infected hepatocytes during a chronic infection, but sufficiently strong to 
cause persistent liver damage. The low level of virus specific CD8 T-cells in the circulation 
of chronically infected patients suggest that HBV- and HCV-specific CTLs are preferentially 
sequestered in the liver [48, 49]. As HBV and HCV are localized and replicate mainly in the liver, 
the immune effector response to these viruses is assumed to be compartmentalized in this 
organ. 
The innate immune response against HBV and HCV
The full development of an efficient antiviral adaptive immune response requires a proper 
activation of components of innate immune response. Natural killer (NK), NK-T cells and proper 
dendritic cells are all necessary both to control the virus replication immediately after infection, 
as well as to deliver the necessary signals that lead to activation of the adaptive response [50]. 
In a transgenic mouse model of HBV infection it has been found that in the early containment 
of acute HBV infection NK-T cell activation inhibits virus replication by the production of IFN 
gamma [51-53]. Furthermore, a rapid drop in viral replication was observed early after acute 
infection of chimpanzees when only resident NK and NK-T cells producing IFN gamma were 
present in the liver [54]. In a study of the incubation phase of acutely infected patients, an 
increase of circulating NK-cells was observed preceding the decline of HBV replication, and 
is followed by the appearance of HBV specific CD8 T-cells, when viral replication had already 
dropped [55]. 
The coexistence of HCV replication with the absence of liver inflammation in the first 4-
6 weeks after HCV infection is indicative for a minimal contribution of NK and NK-T cells to 
the acute phase fase of HCV-induced hepatitis, because IFN gamma production by these 
cells mediates the recruitment of inflammatory cells [56, 57]. Among the intrahepatic cellular 
infiltrates in chronic HCV patients, there is an enrichment of NK cells, NKT cells that may play an 
important role in maintaining chronic liver damage [58, 59]. 
Dendritic cells (DCs) comprise an essential component of the immune system. These cells are 
the most potent antigen presenting cells (APCs) capable of activating naive T cells and are crucial 
for triggering the antigen-specific immune response. DCs are the initators and modulators 
of the helper- and cytotoxic T-cell responses. In infected liver tissue, DCs are thought to be 
present in an immature state. These immature DCs can take up viral particles by phagocytosis. 
The antigens are processed to peptides following their internalization into DCs, resulting in 
the formation of MHC class I and MHC class II-peptide complexes expressed on the surface 
of DCs. Viruses, or virus-infected cells deliver signals that lead to a proper maturation of DCs 
and stimulate their migration to regional lymphoid organs, where they can induce the clonal 
expansion of antigen–specific lymphocytes.
Here, helper T-cells are activated and provide help (a.o. by cytokine secretion) for naive 
cytotoxic T-lymphocytes to differentiate into effector cells. These will then migrate to the target 
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organ to kill the virus-infected hepatocytes or to inhibit viral replication [60, 61]. A recent study 
indicated that DCs generated in vitro from monocytes of patients with chronic HBV-infection 
had impaired T-cell stimulatory capacity [62]. Similar findings have been reported for patients 
with chronic HCV-infection [63]. These findings suggest that alterations of DC function and/or 
maturation during a primary HBV or HCV infection could contribute to a delayed appearance of 
HBV or HCV specific CD8 T-cells after infection. 
Fine needle aspiration biopsy
Until now, studies of the intrahepatic cellular immune responses involved in viral clearance 
have been hampered by the difficulty of frequent sampling of the intrahepatic compartment 
in humans, especially to investigate the intrahepatic immune response during therapy. 
The cytological fine-needle aspiration biopsy (FNAB) procedure represents an a-traumatic 
alternative for the invasive tissue biopsy, and it can be used for frequent monitoring of the 
intrahepatic compartment. This technique was originally developed for the diagnosis of acute 
rejection after kidney transplantation [64] and has been used for monitoring rejection in liver 
transplants for many years [65-68]. Studies of the CD8 mediated T-cell response has been 
restricted to a few immuno-dominant epitopes HBV and HCV. In the present study we have 
introduced this technique for investigating the intrahepatic immune response during chronic 
HBV or HCV infections.
Immune modulating therapy in chronic hepatitis B and C
For treatment of chronic hepatitis B there are three approved drugs: alpha interferon, lamivudine 
and adefovir dipivoxil. Alpha-interferon acts primarily as an immunomodulator of the host 
immune system against viral infection [69]. It enhances expression of HLA class I antigens, and 
HBsAg on the hepatocytes, which will improve the NK cell and CTL mediated killing of infected 
hepatocytes [70]. In addition, it inhibits viral RNA pregenomic packaging into core particles and 
it blocks the entry and uncoating of the virus into uninfected hepatocytes [71]. Alpha interferon 
therapy can result in loss of serum HBeAg in 20 to 40% of the patients. This response is sustained 
in 80-90% of the patients resulting in loss of HBsAg in the years following completion of therapy 
[72, 73]. The main limitations of alpha interferon are the need for subcutaneous administration, 
the frequency of side effects and the limited efficacy. 
Lamivudine and adefovir dipivoxil, in contrast, are potent and effective inhibitors of HBV 
DNA polymerase activity resulting in suppression of HBV DNA, normalization of ALT levels and 
improvement of liver histology in the majority of patients [74, 75]. Both agents are administered 
orally and have few side effects. Suppression of HBV DNA and HBeAg seroconversion occurs 
between 15-40 % of patients [76-78]. However, relapse is common when therapy is discontinued. 
Persistence of ccc-DNA in the nuclei of the hepatocytes during therapy may be responsible for 
this relapse of viral replication [79]. It has been reported that both lamivudine and adefovir 
dipivoxil therapy may restore the CD4 and CD8 T-cell reactivity to HBeAg and HBcAg by a strong 
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HBV DNA reduction [80-81]. Lamivudine therapy restored the T-cell response in HBeAg+ chronic 
HBV patients till the sixth month of treatment, followed by a decline despite the differences in 
viral responsiveness to treatment [82]. 
For chronic hepatitis C, the only therapy available until recently was pegylated-interferon 
alpha treatment, which resulted in sustained remission in a minority of patients [83]. Two 
major multicenter studies have established that the combination interferon alpha and ribivirin 
markedly increased the sustained response rate in previously untreated chronic HCV patients 
[84-86]. Ribavirin, a nucleoside analogue, inhibits viral replication and is administered orally. 
However, monotherapy ribivirin has no significant effect on HCV replication, despite reducing 
the levels of liver enzymes [87].
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OBJECTIVES OF THE STUDY
To investigate the intrahepatic immune response in chronic hepatitis B and C patients, in 
relation to inflammatory liver injury, viral replication and spontaneous or treatment-induced 
viral control.
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ABSTRACT
Cytotoxic T lymphocytes (CTL) and Kupffer cells play an important role in the immune control 
of hepatitis B virus (HBV), but also may induce liver injury during infection. We investigated 
the intrahepatic immune response in liver biopsies of chronic HBV patients in relation to 
inflammatory liver injury and viral control. 
Forty-seven liver biopsies of chronic HBV patients with a varying degree of inflammation (ALT 
values) were selected. Acute hepatitis and normal liver specimens served as controls. Immune 
effector cells, cytotoxic effector molecules and cytokine producing cells were quantified after 
immunohistochemical staining in lobular and portal areas of the biopsies. 
Intralobular number of CD8+ T-lymphocytes was significantly decreased in biopsies of patients 
with high ALT (r=-0.54; p<0.001). Higher ALT-values were correlated with increased numbers of 
granzyme+ cells in portal areas (r=0.65; p<0.001) and higher numbers of intrabolular Fas-L+ 
cells (r=0.32; p=0.05). Fas-L was expressed on Kupffer- and lymphoid cells. More intralobular 
CD8+ T-lymphocytes were found in HBeAg- than in HBeAg+ patients (p=0.002). But IFN-γ and 
TNF-α producing cells were observed sporadically in chronic HBV patients. 
 In chronic HBV infection, low viral replication and HBeAg negativity is related to increased 
presence of intralobular CD8+ T-lymphocytes. Persistence of the virus may be due to the absence 
of cells producing anti-viral cytokines in the liver. Inflammatory liver injury during chronic HBV 
infection is probably not the result of increased numbers of infiltrating CD8+ T-lymphocytes, 
but of Fas-L expression by Kupffer cells and increased cytolytic activity of cells in portal areas.
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INTRODUCTION
Hepatitis B virus (HBV) is a non-cytopathic DNA virus that causes chronic hepatitis in 10% of 
infected adults. Chronic hepatitis may lead to liver cirrhosis or hepatocellular carcinoma [1]. 
Clearance of HBV during acute hepatitis is associated with a strong cytotoxic T lymphocyte 
(CTL) response to the viral proteins [2, 3]. This, together with the knowledge that adoptive 
transfer of virus-specific CD8+ T-lymphocytes can inhibit HBV-replication in HBV-transgenic 
mice [4], indicates that the CTL-response plays an important role in immune control of HBV. 
The mechanism by which CD8+ T-lymphocytes eliminate the virus from the liver is unclear. In 
general CTLs can inhibit viral infection by cytolysis of virus-infected cells through Fas-Ligand-
Fas interaction and the granzyme/perforin pathway or by secretion of antiviral cytokines. 
Experiments with HBV transgenic mice suggest that non-cytolytic mechanisms are responsible 
for HBV clearance [5]. In these mice, intrahepatic secretion of antiviral cytokines, such as IFN-γ 
and TNF-α by CTLs and Kupffer cells can interrupt the HBV life cycle without lysis of infected 
hepatocytes. The rapid reduction of HBV-DNA before hepatocellular damage in acute infections 
in chimpanzees [6] and humans [3] suggest that a similar non-cytolytic mechanism is, at least 
in part, responsible for inhibition of viral replication during natural infection. The liver injury 
following inhibition of viral replication during acute infection is thought to be the consequence 
of an inflammatory response which is mediated by antigen non-specific CD8+ T-lymphocytes, 
but initiated by HBV-specific CD8+ T-lymphocytes [7]. Currently, little is known about the 
mechanisms of immune control of HBV and liver damage during chronic infection with the 
virus. Although peripheral CTL responses are weak during chronic infection [8], hepatocellular 
injury, as reflected in elevated ALT-levels, is frequently observed. Recently, HBV-specific CD8+ 
T-lymphocytes have been demonstrated in the liver during chronic infection, but there was no 
relation between their number and the occurrence of hepatocellular injury nor with the extent 
of immune control of the virus [9]. The role of other possible effector cells, such as natural killer 
(NK) cells, and plasmacytoid dendritic cells, which are the principal IFN-α producers [10], in 
immune control and hepatocyte injury during HBV-infection is as yet unknown. Our aim was to 
investigate which intrahepatic immune effector cells and which immune effector mechanisms 
are related to immune control of HBV and liver damage during chronic HBV-infection. For this 
purpose, we quantitated immune effector cells (CD8+ T-lymphocyte, NK-cells and plasmacytoid 
dendritic cells) and cells expressing cytotoxic effector molecules (granzyme and Fas-Ligand) or 
antiviral cytokines (TNF-α and IFN-γ) in liver biopsies of patients chronically infected with HBV.
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MATERIAL AND METHODS
Patients and liver biopsy specimens
Liver biopsies of chronic hepatitis B patients (n=47) formed the basis of this study. The biopsies 
were diagnostic pretreatment biopsies from patients, which were HBsAg positive for more than 
6 months. Patients treated with any antiviral therapy were excluded. Patients with a co-infection 
of hepatitis C, hepatitis D and patients with a pre-core mutant in the HBV genome were also 
excluded. To obtain a wide range of inflammatory activity in the biopsies, chronic HBV patients 
with low to severe liver inflammation were included (range ALT 11-426)
Subsequently, the patients were stratified according to HBeAg positivity and negativity. 
In addition, liver biopsies of 3 patients with acute and fulminant HBV infection obtained after 
hepatectomy for transplantation and of 2 patients with acute non-viral hepatitis (aetiology 
unknown) were investigated. Normal liver tissue (n=4) was obtained during the resection of 
hepatic malignancies. Liver biopsies were performed in accordance with a standard protocol 
in which a 14-gauge Tru-Cut biopsy needle (diameter 2.1 mm) is used to puncture the right 
lobus of the liver. One part of the liver specimen was fixed in phosphate-buffered formaline 
and embedded in paraffin and a second part of the same specimen was collected in Histocon 
(Polysciences Inc, Warrington PA) and rapidly frozen in isopentane cooled in liquid nitrogen, 
and stored at -80°C. 
Virological assessments
HBsAg, HBeAg, anti-HBe, anti-HCV and anti-HDV were quantitatively determined by IMX (Abbot 
Laboratories, North Chicago, IL). HBV-DNA in sera was measured by Hybrid Capture II microplate 
assay, Digene Corporation, Gaithersburg, U.S.A. Analysis of pre-core mutants was performed by 
a ABI PRISM 3100 genetic analyser with a Big Dye Terminator v3.0 Cycle Sequencing kit (both 
from Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
Antibodies 
CD8 (clone C8/14415) and CD68 (clone PG-M1) mAb were purchased from DAKO, Glostrup, 
Denmark. CD56 (clone N901) was obtained from Beckman Coulter, Hialeah FL. CD123 (clone 
Table 1. Patient characteristics with chronic hepatitis B at time of liver biopsy (n=47)
Variables
Age (years)* 32 (18-70)
Sex (male / female) 27 / 20
ALT (IU/L)* 44 (11-426)
HBV DNA (geq/L)*
HBeAg + / -
Race (Caucasian/Oriental/Black)
1.4E7 (1.0E3 - 9.8E9)
27 / 20
27 / 11 / 9
*median (range)
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Figure 1. Mean total numbers of CD8+ T-lymphocytes in portal areas (a) and mean density of CD8+ T-lymphocytes in lobuli (b) 
of individual liver biopsies of chronic HBV patients in relation to ALT (lines depicted mark the mean of 95% confident interval)
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9F5), and CD178 mAb (clone NOK1) were purchased from BD-Pharmingen, San Jose CA. 
CD178 (clone 5G51) was from Alexis Corporation, San Diego CA. Anti-granzyme mAb (clone 
B7) was kindly provided by professor C.E. Hack of the Central Laboratory of the Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands. MD-2, a mouse mAb specific for IFN-
γ and mAb 61E71, recognizing human TNF-α, were purchased from U-Cytech, Utrecht, The 
Netherlands.
Immunohistochemistry
The distribution of CD8 and CD68 positive cells in the liver was visualized in formalin-fixed, 
paraffin-embedded liver specimens. The liver sections were firstly deparaffinized with xylene 
(Lab Scan Ltd, Dublin, Ireland) and ethanol (Merck, Darmstadt, Germany) and thereafter 
antigen retrieval was performed by temperature-controlled incubation at 99°C in citrate buffer 
(pH 6.0) in a microwave oven for 15 minutes. Incubation with CD8 and CD68 mAb was done 
A
B
Figure 2. Liver biopsy sections immunohistochemically stained with CD8 mAb from chronic HBV patient with normal (A) and 
raised ALT (B) (× 400)
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for 1 hour at room temperature. Slides were washed with TBS (Tris buffered saline) pH 7.3 
supplemented with 0.1% Tween-20. Detection of CD8 positive cells was performed with goat 
anti-mouse immunoglobulins (GAM, DAKO) for one hour followed by alkaline-phosphatase-
anti-alkaline phosphatase complex (APAAP, Serotec, UK). CD68 positive cells were detected by 
secondary biotinylated rabbit anti-mouse antibody (RAM-bio, DAKO), after incubation with 
avidin-biotin blocking solution (DAKO) followed by streptavidine-alkaline phosphatase (DAKO). 
Visualization was performed by incubation in Fast Blue salt / naphtol AS-BI phosphate solution 
supplemented with levamisole (all from Sigma-Aldrich Chemie, Steinheim, Germany). The liver 
specimens were counterstained with Nuclear Fast Red (Fluka Chemie, Buchs, Switzerland). 
Staining of CD56, CD178, CD123 and granzyme B was performed on frozen sections. The slides 
were fixed in 4% paraformaldehyde in phosphate-buffered saline pH 7.3. Unspecific antibody 
binding was prevented by preincubation with TBS supplemented with 10% normal goat serum 
and 10% normal human plasma. Sections were incubated with primary antibodies overnight. 
Detection of primary antibody was performed with the GAM-APAAP procedure. For cytokine 
detection cryostat sections were kept overnight at room temperature in a box with humidified 
atmosphere. Thereafter sections were air-dried for one hour and fixed for 10 minutes in fresh 
acetone, containing 0.02% H2O2. Slides were incubated overnight at 4°C with the primary 
antibodies and subsequently for 30 minutes at room temperature with RAM-bio and avidin-
biotin-HRP complexes, which were added together for 15 minutes. Histochemical revelation 
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Figure 3. Mean numbers of granzyme positive cells in portal areas in relation to ALT
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A
B
Figure 4. Consecutive liver biopsy sections immunohistochemically stained with Fas-L mAb (a) or CD68 mAb (b), showing that 
Fas-L is expressed predominantly on Kupffer cells (× 400)
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of HRP was performed with 3-amino-9-ethylcarbazole (AEC). Slides were counterstained 
with hematoxylin for 10 seconds and mounted in glycerol. Optimal dilutions of all antibodies 
were determined by preliminary experiments on tonsil sections, and on activated peripheral 
blood mononuclear cells (for CD178 antibodies). Negative controls were performed either 
by replacement of the primary mAb by an isotype matched control mAb or by leaving out 
the primary antibody. In each experiment positive control stainings were performed on tonsil 
tissue or activated mononuclear cells. Sections were examined only when tonsil tissue showed 
the expected staining pattern and when the negative control staining was negative.
Quantification and statistical analysis
The liver specimens were microscopically examined at 400 times magnification using a Zeiss 
Axioscop. In every specimen 4-5 fields were randomly selected in liver lobuli to count the 
positive cells, after which the mean was taken for analysis. In portal areas the total numbers of 
positive cells per infiltrate were counted in at least four infiltrates per section. In addition, the 
mean numbers of CD8+ T-lymphocytes per 10,000 µm2 in portal areas were calculated using a 
computer video-image analysis program (KS 400, Kontron Elektronic, GmbH, Eching, Germany). 
For each portal area, color video images of 512 × 512 pixels with a resolution of 0.4348 µm 
per pixel were recorded. All the results were counted by one investigator (T.J.T.) blinded for 
the virological and biochemical conditions of the patients. Data are expressed as mean ± 
standard deviation, unless otherwise indicated. Differences between groups were compared 
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Figure 5. Intralobular density of Fas-L expressing cells in individual liver biopsies in relation to ALT
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using the Mann-Whitney test. Spearman’s correlation coefficients (rs) were used to investigate 
correlations. Linear regression lines in various plots were calculated using the least-squares 
method after logarithmic transformation of both axes. A p-value of < 0.05 was considered 
statistically significant.
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Figure 6. Relation between density of intralobular CD8+ T-lymphocytes and HBeAg status (a) and HBV-DNA (b). ( Medians are 
indicated by a line)
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RESULTS
Characteristics of patients
The initial patient characteristics are presented in Table 1. Forty-seven biopsies of chronic HBV 
patients were investigated. The median age was 32 years (range 18-70); 57% of the patients 
were male. Fifty-seven percent (n=27) were HBeAg positive. The distribution of race was 27 
(57.4%) Caucasians, 11 (23.4%) Orientals and 9 (19.2%) Blacks.
Intrahepatic CD8+ T-lymphocytes in relation to hepatic inflammatory activity 
CD8+ T-lymphocytes were seen both in the portal areas and in the hepatic lobules. There was 
no correlation between the total numbers of the CD8+ T-lymphocytes in portal infiltrates and 
serum ALT values (rs=0.12; p=0.46) (Fig. 1a). Even when the density of CD8+ T-lymphocytes in 
portal areas (i.e. per 10,000 µm2) were calculated by video-image analysis, no correlation was 
found (rs=-0.29; p=0.06). However, an inverse correlation was found between the intralobular 
density of CD8+ T-lymphocytes and serum ALT values. Patients with high ALT values had 
lower numbers of CD8+ T-lymphocytes between the parenchymal cells (rs=-0.54; p<0.001) 
(Fig. 1b, Fig. 2). A significant correlation between serum ALT and HBV-DNA was found (rs=0.41; 
p=0.003).
�
��
��
��
��
��
������������������������ ����������������
�
��
��
��
�
��
���
���
��
��
�
��
���
��
��
��
��
��
��
��
�
�
��
��
��
��
���
������������������������� ����������������
�
��
��
��
�
��
���
���
��
��
�
��
���
��
��
���
��
�
�
�
Figure 7. Density of CD8+ T-lymphocytes versus granzyme-positive cells intralobular (a) and numbers of CD8+ T-lymphocytes 
versus granzyme-positive cells in portal areas
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Cytotoxic effector molecules in relation to hepatic inflammatory activity
To investigate which mechanism might cause inflammatory liver injury observed in chronic 
HBV-patients, biopsy sections were stained for the cytotoxic granule protease granzyme B and 
for CD178 (Fas-Ligand) expression. Granzyme B positive cells were observed in the portal and 
lobular fields of the biopsies from chronic HBV patients. A significant positive correlation was 
observed between serum ALT and the numbers of granzyme B positive cells in portal infiltrates 
and serum ALT values (rs=0.65; p<0.001) (Fig. 3), but not with the density of granzyme B+ cells 
in the lobular fields (rs=0.23; p=0.15).
Expression of Fas-L was observed in all biopsies of chronic HBV patients, predominantly 
in lobular areas. In contrast, no expression of Fas-L was found in normal livers. Clone NOK-1 
confirmed the results obtained by clone 5G51. Fas-L-expressing cells were morphologically 
distinguishable as Kupffer cells and other lymphoid cells. Staining of two serial slides of one 
specimen with CD68 and anti-Fas-L confirmed Fas-L expression on Kupffer cells (Fig. 4). The 
density of Fas-L positive cells between the parenchymal cells was significantly higher in biopsies 
taken during episodes of increased inflammatory liver injury (rs=0.32; p=0.05) (Fig. 5).
Intrahepatic CD8+ T-lymphocytes in relation to viral replication
The relation between immune effector cells and viral control was studied in 47 biopsies. These 
biopsies were from 27 HBeAg positive patients and 20 HBeAg negative patients. The numbers 
of CD8+ T-lymphocytes in the portal areas were equal in the HBeAg positive and in the HBeAg 
negative groups. However, in the HBeAg negative patients the density of CD8+ T-lymphocytes 
in the intralobular areas was higher compared to HBeAg positive patients (p=0.002) (Fig. 6a). A 
inverse correlation was found between serum HBV-DNA and intralobular CD8+ T-lymphocytes 
(rs=-0.44; p=0.002) (Fig. 6b).
The immune effector molecules granzyme B and Fas-L revealed no correlation with HBeAg 
status (data not shown). In all patients the numbers of CD8+ T-lymphocytes (10 ± 5) and 
granzyme B positive cells (13 ± 9) in the hepatic lobules were equal (Fig. 7a), whereas the portal 
fields contained significantly more CD8+ T-lymphocytes (37 ± 19) than granzyme B positive 
cells (14 ± 8; p=0.001) (Fig. 7b). This suggests that all intralobular CD8+ T-lymphocytes have an 
activated cytolytic system, in contrast to those in portal infiltrates.
Other immune effector cells
NK/NKT (CD56 positive) cells were rare in all groups (< 5 per microscopic field), both in portal 
and lobular areas. The number of NK/NKT cells in biopsies of chronic HBV patients was equal to 
normal liver. No difference in numbers of NK/NKT cells was seen in the portal areas or hepatic 
lobules in patients with different ALT, HBeAg status or HBV-DNA (data not shown). 
Monocytes and macrophages, including Kupffer cells (CD68+ cells) were abundant and 
equally present among the groups with different ALT values. CD68 positive cells were mainly 
present within the sinusoids, but some CD68 positive cells were also found in the portal areas 
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(data not shown). Plasmacytoid dendritic cells (CD123 expression) were scarcely observed 
intralobularly (2.0 ± 1.5) and minimally enhanced in comparison with normal liver (0.6 ± 0.8). 
Expression of anti-viral cytokines
IFN-γ expression was sporadically present in all chronic HBV-infected patients (1.0 ± 2.7) 
positive cells per microscopic field). However, in fulminant HBV-infection (n=3), many IFN-γ 
positive cells were detected throughout the biopsy. In these biopsies the architecture of liver 
tissue was severely disturbed; thus lobular and portal area could not be differentiated. In two 
patients with acute non-viral hepatitis we also found a strong expression of IFN-γ, particularly 
in the portal areas. Cells expressing TNF-α were also scarce or absent in chronic patients (0.1 ± 
0.8 positive cells per microscopic field). In patients exhibiting IFN-γ positive cells, TNF-α positive 
cells were observed as well. Again, many TNF-α positive cells were observed in the acute viral 
hepatitis biopsies. Both patients with acute non-viral hepatitis revealed clearly positive cells 
too, but lower in number. They were particularly localized in the portal infiltrates. 
DISCUSSION
In this study we investigated the occurence of intrahepatic immune effector cells, cytotoxic 
effector molecules and IFN-γ and TNF-α expressing cells in relation to inflammatory liver injury 
and viral control during chronic hepatitis B infection. The presence of intralobular CD8+ T-
lymphocytes was most prominent in patients with normal to moderately elevated ALT and less 
noticable in patients with high ALT values. This result extends the observations by Maini et al, 
who reported that a patient chronically infected with HBV with high ALT had lower number 
of CD8+ T-lymphocytes intralobular in comparison to a patient with normal liver enzymes. 
By contrast, in patients with elevated liver enzymes the absolute numbers of intrahepatic 
HBV-specific CD8+ T-lymphocytes were similar to patients without liver damage (9). Together 
these observations indicate that increased numbers of HBV specific or non-specific CD8+ T-
lymphocytes infiltrating the liver parenchyma do not cause inflammatory liver injury during 
chronic HBV-infection. 
We found a higher density of intralobular CD8+ T-lymphocytes in patients with HBeAg-
negativity and low HBV-DNA. This may indicate CD8+ T-lymphocytes are important for immune 
control of viral replication. Although we have not determined whether the intralobular CD8+ 
T-lymphocytes were HBV specific, they were all in an activated state (Fig 7), probably capable of 
attacking virus-infected cells. 
Fas-L expression was found in all chronic HBV-biopsies, but was absent in normal livers. This 
is in agreement with the observations of Galle et al., who described the primary involvement 
of Fas-L in hepatitis B related hepatocellular damage [11]. In our study, Fas-L expression was 
not only found in portal infiltrates, but predominantly in the lobuli. The localization and 
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morphology of the Fas-L expression resembled to a Kupffer cell staining with CD68. Although 
human Kupffer cells were not known to express Fas-L, it has been reported that. IFN-γ treatment 
can induce Fas-L messenger RNA in Kupffer cells in rats [12]. In our study, Fas-L expression in the 
lobuli was clearly upregulated in biopsies taken during episodes of increased ALT, suggesting a 
causative role for Fas-L on Kupffer cells in hepatocyte damage. Data from other studies show an 
upregulation of Fas-L expression by the human immunodeficiency virus in human macrophages, 
which mediates apoptosis of uninfected T-lymphocytes, suggesting that this could be also the 
case in a chronic HBV infection [13-14]. In addition to increased intralobular Fas-L expression, 
a significant positive correllation between granzyme expression in portal infiltrates and 
inflammatory liver injury was found. Since numbers of CD8+ T-lymphocytes in portal infiltrates 
were not increased in patients with high ALT, this suggests that activation of cytotoxic capacity 
of CD8+ T-lymphocytes in infiltrates may be involved in inflammatory injury.
CD56 positive (NK/NKT) cells were rare in all our specimens. The number of these cells in the 
lobuli did not correlate with liver damage or viral control. This does not imply that NK/NKT cells 
do not play any role in the anti-viral immune response, but their role during chronic infection 
is probably limited. These cells may be important for viral control in an early phase of acute 
infection [6]. A previous study has described NK/NKT cells inhibiting HBV replication by secreting 
antiviral cytokines after activation by injection of α-galactosylceramide, a glycolipid antigen, in 
HBV transgenic mice [15] and it was recently reported that inhibition of HBV replication by 
activated NKT cells did not require recruitment of inflammatory cells to the liver [16]. 
By which mechanism the CD8+ T-lymphocytes control virus infection remains unclear. 
Studies using a transgenic mouse model of hepatitis B virus infection have demonstrated that 
virus-specific CD8+ T-lymphocytes can abolish HBV gene expression and replication in the liver 
by secretion of IFN- γ and TNF-α without killing the hepatocytes [4, 5, 6, 17]. We found only few 
IFN- γ and TNF-α producing cells in the biopsies taken during chronic HBV infection. This might 
be due to the insensitivity of the immunohistochemical detection method since cytokines are 
secreted and do not accumulate in the cell. However, we do not favour this explanation, since 
many IFN-γ and TNF-α-positive cells were observed in liver biopsies taken during acute HBV-
infection and clear expression was detected in liver biopsies from acute viral and non-viral 
hepatitis patients. These results suggest that cells producing high amounts of IFN-γ and TNF-α 
are not present during chronic HBV-infection. The failure of prominent intrahepatic cytokine 
production observed in this study could therefore explain the viral persistence, even in those 
patients in which replication was suppressed. This failure was not due to a resting state of 
intrahepatic CD8+ T-lymphocytes.
CD8+ T-lymphocytes and NK-cells, once activated use the same the same lytic pathway for 
mediating target cell death. The equal numbers of intralobular granzyme B positive cells and 
CD8+ T-lymphocytes suggest that these CD8+ T-lymphocytes were activated. We cannot exclude 
prior release by the granzyme-negative expression of lymphocytes due to cell activation, but it 
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is widely accepted that once lytic granules mobilization has been initiated in the effector cell, it 
reflects the activated status of a CD8 T-lymphocyte toward a target cell [18].
CD123 expressing plasmacytoid dendritic cells were hardly increased in chronic HBV liver 
biopsies compared to normal liver tissue indicating that these IFN-α producers are not implicated 
in control of HBV replication during chronic infection. Donaghy et al reported that increasing 
viral load was correlated with depletion of myeloid and plasmacytoid DCs in blood of patients 
with an HIV-1 infection. It was suggested that disease progression was due to the loss of both 
DC populations in HIV infection [19]. The important function of PDCs was clearly demonstrated 
by Cella et al who showed that human PDCs stimulated with influenza virus and CD40-Ligand 
in vitro could not only produced IFN-α, but also efficiently induce a Th1 response. [20]. Possibly, 
chronicity of HBV-infection may, in addition to absence of IFN-γ and TNF-α producing cells, be 
due to a paucity of IFN-α producing cells in the infected liver. 
In conclusion, low HBV replication and HBeAg negativity is associated with a larger number 
of intralobular CD8+ T-lymphocytes. Intralobular CD8+ T-lymphocytes were all activated cells 
and contained granzyme B, a marker of the lytic pathway, but did not produce high levels of 
cytokines. Increased Fas-L expression on Kupffer cells and increased cytolytic activity of cells in 
portal infiltrates among patients with severe liver inflammation appears to play a major role in 
the pathophysiology of liver injury during chronic HBV infection.
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ABSTRACT
Recognition of HBV-infected hepatocytes by CD8 T-lymphocytes is important for viral clearance. 
Expression of hepatitis B core antigen (HBcAg) in HBV-infected hepatocytes can trigger this 
antiviral T-cell response. The intrahepatic CD8 T-lymphocytes and HBcAg expression were 
investigated in relation to response to antiviral therapy. 
Forty chronic HBeAg-positive patients treated with either lamivudine (n=20) or interferon-
alpha (n=20) were investigated. Ten patients from each treatment group exhibited a response. 
Liver biopsies were carried out before and after therapy. CD8 T-lymphocytes and HBcAg 
expression were detected by immunohistochemistry. The number of pretreatment intrahepatic 
CD8 T-lymphocytes was significantly higher in responders (p=0.008). In responders baseline 
nuclear HBcAg expression tended to be lower (p=0.09). Cytoplasmic expression was not 
significantly different between responders and non-responders (p=0.46). The number of CD8 
T-lymphocytes correlated with cytoplasmic HBcAg (rs=0.31; p= 0.04); CD8 T-lymphocytes were 
situated in clusters of hepatocytes with cytoplasmic HBcAg. Longitudinal analysis showed a 
significant reduction of CD8 T-lymphocytes after treatment in responders (p<0.001). Multivariate 
analysis revealed pretreatment CD8 T-lymphocytes and age as independent prognostic factors 
for response (n=40). The number of pretreatment CD8 T-lymphocytes was the only independent 
prognostic indicator for response to interferon-alpha (p=0.03); it was of borderline significance 
for lamivudine therapy (p= 0.06).
It is concluded that the number of pretreatment intrahepatic CD8 T-lymphocytes is an 
important predictor of response to HBV therapy with either interferon-alpha or lamivudine. 
Response to therapy led to a significant reduction of intrahepatic CD8 T-lymphocytes. Co-
localisation of CD8 T-lymphocytes and HBcAg-positive hepatocytes suggests antiviral activity 
predominantly at the site of maximum HBV replication.
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INTRODUCTION
More than one-third of the global population has been infected with the hepatitis B virus 
(HBV) and approximately 350 million people are chronic carriers of HBV. These patients have 
an increased risk of developing liver cirrhosis and hepatocellular carcinoma [1]. Spontaneous 
remission with effective control of viral replication occurs in a small number of patients during 
the natural history of chronic HBV infection. These remissions are the desired result of antiviral 
treatment for chronic HBV. The drugs interferon-alpha and lamivudine are used to treat chronic 
HBV infection, but only a small number of patients (20-30%) achieve a sustained response to 
these antiviral agents [2, 3]. Recent studies provide substantial evidence that the host antiviral 
immune response, in particular the intrahepatic immune response, to HBV-antigens is the main 
determinant of the outcome of HBV infection [4]. Hepatitis B core antigen (HBcAg) in the infected 
liver is associated with active viral replication [5, 6]. During an active and ongoing hepatitis, 
HBcAg is localized predominantly in the cytoplasm of the infected hepatocyte. However, in 
patients with no or minimal inflammatory activity, HBcAg is found mainly in the nucleus. 
These findings have led to the hypothesis that infected hepatocytes with a cytoplasmic or 
membraneous HBcAg expression trigger CD8 T-lymphocytes, resulting in cytolysis of infected 
hepatocytes [7]. We investigated the predictive value of the number of CD8 T-lymphocytes 
and HBcAg expression in the liver in relation to response to antiviral therapy for chronic HBV 
patients. 
MATERIAL AND METHODS
Patients and controls
Forty patients with chronic hepatitis B (HBsAg, HBeAg and HBV-DNA positive for more than 6 
months) were studied. Twenty patients received interferon-alpha (Intron A, 10 MU thrice weekly 
subcutaneously for 32 weeks) and 20 patients received lamivudine therapy (100 mg/day po for 
11 to 169 weeks). To achieve optimal data on the mechanism of response to antiviral therapy 
for both regimens we selected a population with 50% response in both treatment groups. A 
control group comprised 5 healthy subjects without evidence of exposure to the HBV virus (i.e. 
HBsAg and anti-HB core negative). The definition of response consisted of HBeAg negativity 
and HBV-DNA levels below the detection limit (<1.0 E5 HBV-DNA copies/mL) at the end of 
therapy. All patients were negative for antibodies against human immune deficiency virus 
(HIV), hepatitis C and hepatitis D. A liver biopsy was obtained before therapy and at the end 
of treatment. The liver specimens were fixed in phosphate-buffered formalin and embedded 
in paraffin. The study was approved by the Medical Ethical Committee of the Erasmus Medical 
Center and written informed consent was obtained prior to therapy.
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Virological assessments
HBsAg, HBeAg, anti-HBe, anti-HIV, anti-HCV and anti-HDV were determined quantitatively by 
IMX (Abbott Laboratories, North Chicago, IL) according to the manufacturer’s instructions. HBV-
DNA level in sera was measured by Hybrid Capture II microplate assay (Digene Corporation, 
Gaithersburg, U.S.A.), as described by the manufacturer. 
Detection of CD8 T-lymphocytes and HBcAg in the liver
CD8 T-lymphocytes and HBcAg expression in hepatocytes were examined by 
immunohistochemical double stain with CD8 mAb (clone C8/14415) and rabbit anti-HBcAg 
from DAKO, Glostrup Denmark. The liver sections were first deparaffinized with xylene (Lab 
Scan Ltd, Dublin, Ireland) and ethanol (Merck, Darmstadt, Germany). The antigen retrieval was 
performed by temperature-controlled incubation at 99°C in citrate buffer (pH 6.0) in a microwave 
oven, followed by incubation with CD8 mAb. The liver specimens were incubated with goat 
anti-mouse immunoglobulins (GAM, DAKO), followed by alkaline-phosphatase-anti-alkaline 
phosphatase complex (APAAP, Serotec, UK). Subsequently, the specimens were incubated with 
rabbit anti-HBcAg. Hepatic HBcAg expression was detected by an immunoperoxidase kit (En 
Vision HRP system, DAKO). The order of revealing the two antigens was initial incubation with 
diaminobenzidine for the HBcAg expression and secondly with Fast Blue salt / naphtol AS-BI 
phosphate solution supplemented with levamisole (all from Sigma-Aldrich Chemie, Steinheim, 
Germany) for the visualization of CD8 T-lymphocytes. Negative controls were performed by 
replacement of the primary mAb by an isotype-matched control mAb.
Quantitation and statistical analysis
The liver specimens were examined microscopically (Zeiss Axioscop) at 400X. In every 
specimen 10 fields were selected at random in liver lobuli to count the CD8 T-lymphocytes 
and hepatocytes with HBV core expression (nuclear and cytoplasmatic). The mean of all counts 
was used for analysis. All results were counted by one investigator (T.J.T.), who was blinded 
for response and treatment regimen of the patients. Statistical analysis of differences between 
groups was performed with the Mann-Whitney U test. Pretreatment and posttreatment levels 
within each group were compared using the Wilcoxon signed rank test. Spearman’s correlation 
coefficients (rs) were used to investigate correlations. Univariate analysis was conducted to 
investigate the presence of covariation of response with baseline variables. Variables that 
were statistically significant (two sided, p<0.05) or exhibited a marginal association (p≤0.10) 
according to univariate analysis were subsequently introduced into multivariate analysis, 
which was assessed by logistic regression analysis. SPSS 9.0 for Windows (SPSS, Chicago, IL) 
was used for all statistical analysis. In all analyses a p- value of <0.05 was considered statistically 
significant. Data are expressed as median (range), unless indicated otherwise.
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RESULTS
Patient characteristics
Baseline characteristics of responders and non-responders are shown in Table 1. Responders 
had lower levels of hepatitis B virus DNA than non-responders. The distribution of gender, 
age, race and serum alanine aminotransferase levels and race was not significantly different 
between responders and non-responders.
Table 1. Baseline characteristics
All patients
(n=40)
Responders
(n=20)
Non-responders
(n=20)
p-value: response 
vs. non-response
Sex (male/female) 34 / 6 17 / 3 17 / 3 n.s.
Age (years)* 28 (16-64) 34 (15-64) 25 (16-61) 0.08
ALT (units/L)* 79(20-786) 84 (20-786) 76(31-244) 0.43
HBV-DNA (geq/mL)* 3.0 E8 
(6.6 E5-1.4 E10)
1.3 E8
(6.6 E5-3.5 E9)
5.4 E8
(1.5 E6-1.4 E10)
0.01
Race (C/ A/ B)** 29/ 9/ 2 17/ 2/ 1 12/ 7/ 1 n.s.
*   median (range)
** C=caucasians A=asians B= Africans
Pretreatment intrahepatic CD8 T-lymphocytes and HBcAg in relation to treatment response 
Pretreatment numbers of CD8 T-lymphocytes were significantly higher in responders than in 
non-responders (p=0.008) (Table 2). The number of hepatocytes with nuclear HBcAg expression 
tended to be lower in responders than in non-responders (p=0.09) (Table 2). No correlation 
was observed between the number of CD8 T-lymphocytes and nuclear expression of HBcAg 
in hepatocytes (rs=0.23; p=0.13). Median cytoplasmic expression of HBcAg was 2.5 (range 
0-29) in responders vs. 1.5 (range 0-21) in non-responders (p=0.46). A significant correlation 
between numbers of CD8 T-lymphocytes and hepatocytes with cytoplasmic expression of 
HBcAg was observed (rs=0.32; p=0.04). Furthermore, these CD8 T-lymphocytes were situated 
predominantly within the vicinity of hepatocytes with cytoplasmatic HBcAg expression. Nuclear 
and cytoplasmic HBcAg expression in relation to CD8 T-lymphocytes are shown in figure 1. 
Table 2. Expression of CD8 T-lymphocytes and HBcAg in pre-treatment biopsy
All patients
(n=40)
Responders
(n=20)
Non-responders
(n=20)
p-value: response 
vs. non-response
Number CD8 
T-lymphocytes*
12.0 (3-31) 15.5 (5-31)  9.5 (3-26) 0.008
Number nuclear HBcAg 
hepatocytes*
 8.0 (0-49)  4.0 (0-45) 12.5 ( 1-49) 0.09
Number cytoplasmic HBcAg 
hepatocytes*
 2.0 (0-33)  2.5 (0-33) 1.5 (0-21) 0.46  
median (range)
* per microscopic field 
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A
B
Figure 1. Immuno double-stain of HBcAg and CD8 T-lymphocytes (brown=HBcAg; CD8 T-lymphocytes=blue). Scattered 
nuclear expression of HBcAg and CD8 T-lymphocytes (original magnification × 200) (A). Clustered cytoplasmic expression of 
HBcAg (original magnification × 100) and co-localisation of cytoplasmic HBcAg and CD8 T-lymphocytes (inserted left, original 
magnification × 200) (B).
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Univariate analysis of the pretreatment co-variables of response - age (p=0.08), ALT level 
(p=0.43), HBV-DNA level (p=0.01), CD8 T-lymphocytes (p=0.008), nuclear HBcAg expression 
(p=0.09) and cytoplasmic HBcAg expression (p=0.46) - revealed only CD8 T-lymphocytes as 
a significant predictor of response (Table 1 and 2). In multivariate analysis, age (p=0.02) and 
pretreatment number of CD8 T-lymphocytes (p=0.007) emerged as independent variables 
of significance for response (Table 3). The predicted probability of subsequent response to 
antiviral therapy according to the regression modeling of the pretreatment numbers of CD8 
T-lymphocytes is shown in figure 2. Serum ALT did not emerge as predictor for response while 
CD8 T-lymphocytes was identified as a strong predictor. However, serum ALT and the quantity 
of CD8 T-lymphocytes did correlate significantly (rs=0.45, p=0.004), indicating that these two 
variables were both associated with active liver disease. 
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Figure 2. The predicted probability of subsequent response to therapy displayed as a function of the number of CD8 
T-lymphocytes per lobular field in biopsies taken before treatment. The curve is based on logistic regression modeling of 
pretreatment CD8 T-lymphocytes. Individual datapoints of responders and non-responders are depicted.
Table 3. Results of multivariate analysis (n=40)
Odds ratio 95% CI p-value
Age 1.08 1.01-1.15 0.02
CD8 T-lymphocytes 1.20 1.05-1.37 0.007
CI: confidence interval
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Alteration of intrahepatic CD8 T-lymphocytes and HBcAg during antiviral treatment 
Longitudinal analysis of pretreatment and posttreatment biopsies from the responders showed 
a significant reduction of CD8 T-lymphocytes (p<0.001) (Fig. 3a), while the numbers of CD8 T-
lymphocytes remained unchanged in the non-responders (p=0.71) (Fig. 3b). Nuclear expression 
(p<0.001) and cytoplasmic expression (p=0.003) of HBcAg in the hepatocytes decreased 
significantly in the responders (Fig 4a and Fig. 4b). In contrast, no significant reduction of nuclear 
(p=0.06) or cytoplasmic (p=0.97) expression of HBcAg was observed in the non-responders 
(Fig. 4c and Fig. 4d)
Interferon-alpha and lamivudine treatment: subgroup analysis for intrahepatic CD8 T-lymphocytes and 
HBcAg
Age, sex, race, and serum values for ALT and HBV-DNA did not differ across the treatment groups. 
Pretreatment densities of CD8 T-lymphocytes and HBcAg were also comparable between 
treatment groups and alteration during therapy did not differ significantly between patients 
treated with interferon-alpha and lamivudine (data not shown). The response rate 6 months 
after discontinuation of therapy was 70% for interferon-alpha and 10% for lamivudine. This 
difference in sustained response could be explained by a state of immune control induced by 
interferon-alpha, but not lamivudine. Therefore, we hypothesized that the immune modifying 
effect of interferon-alpha might have led to a different pattern in CD8 response than the 
predominantly antiviral effect of lamivudine. However, in both treatment groups pretreatment 
CD8 T-lymphocytes were higher in responders than in non-responders and during therapy a 
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Figure 3. Densities of intralobular CD8 T-lymphocytes in serial liver biopsy specimens before therapy and at the end of 
treatment of responders (A) and non-responders (B). Median and ranges are depicted at the top.
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Figure 4. Serial liver biopsy specimens before therapy and at the end of treatment of responders in relation to nuclear (A) and 
cytoplasmic expression (B) of HBcore and non-responders in relation to nuclear (C) and cytoplasmic expression (D) of HBcAg. 
Median and ranges are depicted at the top.
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similar reduction in CD8 T-lymphocytes was found for interferon-alpha and lamivudine treated 
patients: In interferon-alpha responders median CD8 T-lymphocyte number was 13.5 (range 
5-31) before treatment and 8.5 (range 5-11) after treatment (p=0.01); in non-responders the 
median number of CD8 T-lymphocytes remained about the same (pretreatment 7.5 (range 3-
15) vs. posttreatment 10.0 (range 5-21); p=0.56). In lamivudine responders median numbers of 
CD8 T-lymphocytes decreased from 19 (range 5-30) pretreatment to 9.5 (range 7-16) (p=0.01) 
posttreatment; in lamivudine non-responders median CD8 T-lymphocytes were comparable 
before and after treatment (pretreatment 11.5 (range 5-26) vs. posttreatment 9 (range 4-26); 
p=0.28). 
Univariate analysis for baseline characteristics of patients treated with interferon-alpha 
showed that the number pretreatment CD8 T-lymphocytes (p=0.03) was the only predictor 
of response. Age, HBV-DNA, serum ALT level, nuclear HBcAg and cytoplasmic HBcAg did not 
emerge as predictors of response. After multivariate analyses pretreatment CD8 T-lymphocytes 
remained the only independent prognostic indicator of response. In the lamivudine-
treated patients, univariate analysis did not yield any significant predictors of response. In 
the multivariate analysis age (p=0.05) and pretreatment CD8 T-lymphocytes (p=0.06) were 
borderline independent indicators of response. 
DISCUSSION
In the present study intrahepatic CD8 T-lymphocytes were strongly associated with response to 
antiviral therapy in two different ways. Firstly, the pretreatment number of intrahepatic CD8 T-
lymphocytes was higher in responders than in non-responders and, secondly, intrahepatic CD8 
T-lymphocytes decreased significantly during therapy in responders whereas they remained 
unchanged in non-responders. Both phenomena were found in patients treated with either 
interferon-alpha or lamivudine.
The importance of CD8 T-lymphocytes has been well documented in acute HBV infection 
where a strong CD8 T-lymphocyte response is associated with viral clearance [8, 9]. It is 
generally acknowledged that this CD8 T-lymphocyte response is antigen specific, present in the 
liver, and able to clear HBV infection by cytolytic and noncytolytic effector functions [10]. The 
CD8 T-lymphocytes are specific for a range of different epitopes within HBV core, polymerase 
and envelope proteins [11, 12]. In contrast to acute HBV infection, chronic HBV carriers exhibit 
a weak peripheral CD8 T-lymphocyte response [13, 14]. A recent study demonstrated the 
existence of HBV-specific CD8 T-lymphocytes in the liver of chronic HBV carriers, but there 
appeared no relation between their number and the occurrence of hepatocellular injury [15]. 
However, these authors observed that the total numbers of CD8 T-lymphocytes (either HBV-
specific or non-specific) was increased in liver biopsies of patients with hepatocellular injury, 
which is in agreement with the present observation that numbers of intrahepatic CD8 T-
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lymphocytes are positively correlated with ALT values. Since in their study the patients groups 
with high and low viremia strongly differed in ALT-values, no definitive conclusion could be 
drawn on the relation between total or HBV-specific CD8 T-lymphocytes and immune control 
of viral replication. Our study in which responders and non-responders did not differ in ALT-
value, allowed to investigate the relation between total intrahepatic CD8 T-lymphocytes and 
response to therapy independently of the extent of hepatocellular inflammation. We found 
that the total numbers of intrahepatic CD8 T-lymphocytes was higher in pre-treatment liver 
biopsies of responders as compared to non-responders. It remains to be established, however, 
whether this difference reflects as difference in the quantity of virus-specific T-lymphocytes. 
Also non-HBV specific bystander T-lymphocytes may contribute to clearance of the virus, e.g. 
by secretion of antiviral cytokines. In the current study we did not investigate the cytolytic and 
antiviral effector mechanisms expressed by CD8 T-lymphocytes, but previous studies have 
shown that CD8 T-lymphocytes can induce inflammatory liver injury by induction of apoptosis, 
mediated by Fas Ligand and cytolytic granzyme molecules [16, 17].
In the setting of antiviral treatment little is known about the intrahepatic response of CD8 T-
lymphocytes. It is possible that responders have a pre-existent T-cell response, which is unable 
to clear the virus completely. Viral clearance can be achieved either by boosting the immune 
response with an immunemodulator or by lowering the viral load. Additional factors such as 
HBV genotype and viral mutations may have an effect on the establishment of viral control. 
Several antiviral regimens are targeted to boost the HBV-specifc CD8 T-cell response, either by 
immune modulation or by inhibition of viral replication. For guidance of antiviral management, 
our results showed that the number of intrahepatic CD8 T-lymphocytes could be helpful to 
predict subsequent response to antiviral therapy. However, it should not be interpreted as proof 
that low numbers of CD8 T-lymphocytes have no prognostic value for response. Other strong 
predictors of response, such as serum ALT and HBV-DNA, should also be assessed to determine 
the optimum therapeutic regimens for chronic HBV patients [18, 19]. Furthermore, it should 
be mentioned that since the number of patients is relatively small, the factors found to be 
predictive of response by means of multivariate analysis can only be considered as probable.
Subgroup analysis revealed that the number of pretreatment intrahepatic CD8 T-lymphocytes 
was the only prognostic indicator for response to interferon-alpha therapy, while it emerged as a 
borderline independent indicator for response to lamivudine therapy. Interestingly, the 6-month 
response rate after discontinuation of therapy was 70% for interferon-treated patients and 10% 
for lamivudine-treated patients. This suggests that inhibition of viral replication by lamivudine 
alone does not result in HBV elimination and interferon-alpha-induced immune reactivity 
is required for complete control [20-22]. The quantity and response of intrahepatic CD8 T-
lymphocytes cannot explain this difference in response pattern, as these were similar for patients 
treated with lamivudine or interferon-alpha. In peripheral blood Marinos et al. compared T-cell 
responses in chronic HBV patients during interferon-alpha therapy and combined interferon-
alpha-lamivudine in patients who did not respond previously to interferon-alpha monotherapy. 
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They observed no difference in T-cell response during interferon-alpha monotherapy and 
during combination, and concluded that significant inhibition of viral replication by lamivudine 
did not restore the hyporesponsiveness in chronic HBV [23]. In contrast, Boni et al. reported 
that in chronic HBV patients undergoing lamivudine treatment, reduction in viral load allows 
repopulation of functionally active HBV specific CD8 T-lymphocytes in peripheral blood [24]. A 
possible explanation of these contradictory data could be a difference in duration of infection 
in both studies. To further dissect the difference in response mechanism between interferon-
alpha and nucleoside analogues we are currently investigating the function and HBV specificity 
of intrahepatic CD8 T-lymphocytes during therapy with antiviral agents.
The presence of HBcAg in the infected hepatocytes is associated with active replication. In 
our study serum HBV-DNA level correlated with nuclear (rs=0.45; p=0.004) but not cytoplasmic 
expression of HBcAg (rs=0.17; p=0.29). HBcAg expression is found predominantly in the nucleus 
of patients with minimal hepatitis activity, while HBcAg is prominent in the cytoplasm of 
patients with active and ongoing hepatitis [7, 25-27]. In our responders we not only observed 
a significant reduction of intrahepatic numbers of CD8 T-lymphocytes but also an almost 
complete dissappearance of HBcAg-infected hepatocytes at the end of therapy. Patients with 
predominant cytoplasmic HBcAg expression had higher levels of CD8 T-lymphocytes in the 
lobular fields (p=0.04). Moreover, these CD8 T-lymphocytes were situated predominantly in 
hepatocyte clusters with HBcAg expression in the cytoplasm. Both the combined reduction of 
CD8 T-lymphocytes and HBcAg-positive hepatocytes after successful antiviral therapy as well 
as the co-localisation of CD8 T-lymphocytes and HBcAg-positive hepatocytes within the liver 
parenchyma indicate that responders have higher numbers of intrahepatic CD8 T-lymphocytes 
able to exert antiviral activity at the site of maximum replication. An efficient immunological 
response will result in a lowering of the viral load and, consequently, CD8 T-lymphocytes 
numbers would fall with the decrease of HBcAg-infected hepatocytes. Further studies are 
needed to elucidate whether the CD8 T-lymphocytes present in the lobular fields at the end of 
therapy could be primarily HBV-specific. HBV-specific CD8 T-lymphocytes can persist long after 
recovery of HBV-infection, despite low levels of HBV DNA [28]. 
In conclusion, immunohistochemical analyses of a series of patients with chronic hepatitis 
B infection treated with antiviral therapy revealed that responders exhibit an increased 
pretreatment number of intrahepatic CD8 T-lymphocytes. The pretreatment number of 
intrahepatic CD8 T-cells was found to be an independent predictor of response for therapy with 
interferon-alpha or lamivudine. Co-localisation of intrahepatic CD8 T-lymphocytes and HBcAg-
infected hepatocytes suggests that CD8 T-lymphocytes are able to expand and exert antiviral 
activity at the site of maximum HBV replication in the liver. 
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ABSTRACT
Frequent analysis of the intrahepatic cellular immune response during chronic hepatitis B 
infection is not feasible with the liver tissue biopsy technique, due to its risk profile and patient 
discomfort. We investigated whether the relatively safe and patient-friendly cytological Fine-
Needle Aspiration Biopsy technique (FNAB) is suited for this purpose. FNABs taken during 
hepatitis flares in three chronic hepatitis B patients treated with IFN-α, showed significant 
increments of CD8+-lymphocytes compared with the FNABs taken before and after the 
flares. No increments were observed in peripheral blood. The increments of intrahepatic 
CD8+-lymphocytes detected by the FNAB were related to anti-viral immune reactivity, since 
they coincided with significant serum HBV-DNA level reductions and in two of three patients 
with HBeAg seroconversion. In conclusion, the FNAB-technique is suited to investigate the 
intrahepatic immune response during chronic hepatitis B infection on a frequent basis.
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INTRODUCTION
Hepatitis B virus (HBV) is a non-cytopathic DNA virus that causes chronic hepatitis in 10% 
of infected adults. Chronic hepatitis may ultimately lead to liver cirrhosis or hepatocellular 
carcinoma. Successful treatment regimens for chronic hepatitis B virus (HBV) infection consist 
of immune-modulation with interferon-α or direct inhibition of viral replication with nucleoside 
analogues. However, only part of the patients respond to these treatments with sustained 
control of the virus. It is at present unknown why some patients respond and others do not. 
During acute hepatitis the virus is thought to be eliminated by an HBV-specific cytotoxic T-
lymphocyte (CTL) response, which is detectable in peripheral blood [1, 2]. However, during 
chronic infection, few anti-viral CTLs can be detected in the circulation [3], since they are 
compartmentalized to the liver [4]. It has been hypothesized that differences in the intrahepatic 
immune response are responsible for differences in outcome of antiviral therapy [5].
Several investigators have correlated intrahepatic CD8 T-lymphocytes to liver inflammation 
in tissue biopsies obtained during acute and chronic hepatitis B infections [6-8]. However, 
studies with longitudinal analysis of the cellular immune response in the liver during de novo 
infection or treatment of chronic hepatitis B infection have not been performed yet, due to the 
invasiveness and related patient discomfort of the liver tissue biopsy. 
Since the early eighties, the cytological Fine-Needle Aspiration Biopsy (FNAB) has been used 
for monitoring rejection activity after liver transplantation [9]. Here, we investigated whether 
the FNAB technique is suited for monitoring the intrahepatic immune response during acute 
exacerbations of hepatitis during antiviral therapy for chronic HBV-infection. 
MATERIAL AND METHODS
Patients
FNABs from three chronic HBeAg+ HBV-infected patients, who had acute hepatitis exacerbations 
(defined as an increase of serum alanine transaminase (ALT) to above 10 times upper limit of 
normal) during a 12-month therapy with pegylated-interferon (100 µg s.c. per week) were 
investigated in this study. Patient 1 was a female and 33 years of age, patient 2 a male and 29 
years of age, patient 3 a male and 42 years of age. All three were included in a clinical study 
in which FNABs and peripheral blood specimens were obtained at the start of therapy and at 
weeks 2, 8 and 52 (end of therapy) to study the intrahepatic immune response. In addition, 
FNABs were performed during hepatitis flares. The study was approved by the local Medical 
Ethical Committee, and all subjects gave written informed consent. 
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FNAB-procedure
The FNABs were performed using a 25 Gauge needle (diameter 0.5 mm) and therefore much 
better tolerated than core biopsies (14 Gauge, 2.0 mm). The needle was inserted in the eighth 
or ninth right intercostal space without any anaesthesia. A syringe with culture medium was 
attached to the biopsy needle and a specimen was obtained from the liver through aspiration 
caused by negative pressure in the syringe by making a short to-and-fro movement. In addition, 
heparinized peripheral blood was obtained by venapunction. In total, two FNABs and one 
sample of peripheral blood were collected per visit. FNAB and blood cells were centrifuged 
on to glass slides using a cytocentrifuge. One cytospin preparation of each specimen was 
stained according to the May-Grünwald-Giemsa procedure. The FNABs were considered to be 
representative if the aspirate contained at least seven hepatocytes per 100 leucocytes [10, 11]. 
If both FNABs were representative, the specimen with the highest hepatocyte/leukocyte ratio 
was used in the study.
Immunocytochemistry
Cytospin specimens of FNAB and peripheral blood were immunocytochemically stained with 
mouse antibodies specific for CD4+ T-lymphocytes (clone SK3, B&D, San Jose, CA), CD8+ T-
lymphocytes (clone MEM-31, Monosan, Uden, the Netherlands), B-lymphocytes (CD19, clone 
HD-37, DAKO, Glostrup, Denmark), NK/NKT cell (CD56, clone N901 from Beckman Coulter, 
Hialeah, FL) and plasmacytoid dendritic cells (CD123, clone 9F5, from BD-Pharmingen, San 
Jose CA), as described in [12]. Briefly, the slides of FNAB and blood specimens were fixed in 
4% paraformaldehyde in phosphate-buffered saline pH 7.3. Unspecific antibody binding was 
reduced by preincubation with TBS (Tris-buffered saline; pH 7.3) supplemented with 10% normal 
goat serum and 10% normal human plasma. Sections were incubated with primary antibodies 
or with isotype-matched control antibodies overnight at 4°C, and afterwards washed with TBS 
supplemented with 0.1% Tween-20. Detection of positive cells was performed with goat anti-
mouse immunoglobulins (GAM, DAKO) for one hour followed by alkaline-phosphatase-anti-
alkaline phosphatase complex (APAAP, Serotec, Oxford, UK). Visualization was performed by 
incubation in Fast Blue salt / naphtol AS-BI phosphate solution supplemented with levamisole (all 
from Sigma-Aldrich Chemie, Steinheim, Germany). The slides were counterstained with Nuclear 
Fast Red (Fluka Chemie, Buchs, Switzerland). Numbers of positive cells in immunocytochemical 
stains were quantified per 1000 leucocytes. 
Virological assessment
Quantitative determination of HBV-DNA was performed by a TaqMan assay, which allowed the 
accurate determination down to 373 geq/ml in serum. The assay was calibrated using EUROHEP 
standards [13].
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RESULTS AND DISCUSSION 
Numbers of CD8+ T-lymphocytes are elevated in FNAB but not in peripheral blood during hepatitis 
exacerbations
The hepatitis flares during therapy in the three selected patients occurred at 17, 28 or 48 
weeks after start of therapy. In addition, patient 1 experienced a post-treatment flare at week 
73. As is shown in Figure 1A, the FNABs obtained during the hepatitis flares contained many 
lymphocytes. Figure 1B shows an immunocytochemical CD8-stain of a FNAB cytospin. 
Quantification of immunocytochemically stained leukocytes in FNAB- and peripheral blood 
cytospin preparations obtained during and after therapy from patient 1 showed that during 
hepatitis flares the relative numbers of CD8+ T-lymphocytes increased in the FNABs, but not 
in peripheral blood specimens (Figure 2). A comparable increase of CD8+ T-lymphocytes was 
observed during the hepatitis flares in the two other patients (Figure 3). In addition to the 
increase in CD8+ T-lymphocytes, an elevated number of CD4+ T-cells was observed in the FNAB 
taken during the hepatitis flare in patient 3 (Figure 3B). Such a clear CD4+ T-cell increase was not 
found in the other two patients. No increments of CD19+, CD56+ or CD123+ cells were observed 
during the hepatitis flares in any of the patients (data not shown). 
The intrahepatic cellular immune response detected by the FNAB-technique reflects anti-viral immune 
reactivity.
The increments of CD8+ T-lymphocytes in FNABs during the hepatitis flares coincided in all 
three patients with a reduction in HBV-DNA level of at least 2 logs (Figure 2 and 3A). As is shown 
in Figure 2, the CD8+ T-lymphocyte increment in the FNAB during the first flare in patient 1 
was followed by HBeAg seroconversion. Unfortunately, HBeAg reactivation was observed after 
A B
Figure 1. A: May-Grünwald-Giemsa-stained cytospin preparation of a FNAB obtained during a hepatitis flare containing many 
lymphocytes. The large cells are hepatocytes. B: Immunocytochemical CD8-stain (red) of a FNAB cytospin preparation obtained 
during a hepatitis flare.
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cessation of therapy. In patient 2 the hepatitis flare was not followed by HBeAg seroconversion, 
while in patient 3 it was followed by sustained seroconversion. Interestingly, this was the only 
patient which showed, in addition to an increase of CD8+ T-cells, also an increment of CD4+ 
T-helper cells in the FNAB during the flare. Apparently, elevations of intrahepatic lymphocytes 
detected by the FNAB-technique reflected anti-viral immune reactivity.
Until now about 450 FNABs have been performed in our center in liver transplant recipients 
and in patients with chronic liver diseases and no complications were observed. The reported 
patient discomfort was comparable to a venepuncture. Other investigators have reported 
similar results in liver transplant recipients [10]. 
In conclusion, our results show that the FNAB-technique allows investigation of the 
intrahepatic cellular immune activity during antiviral therapy of chronic hepatitis B infection 
at a regular basis. 
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Figure 2. Course of ALT (U/L), HBV-DNA (genome equivalents/mL), and HBeAg positivity (panel A), and of the number of 
CD8+ and CD4+ T-lymphocytes in FNAB and peripheral blood per 1000 leucocytes (panel B) in patient 1 during and after IFN-α 
therapy.
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Figure 3. A: Course of ALT (IU/L) and HBV-DNA (genome equivalents/mL) of patient 2 and 3 during IFN-α therapy. B: Numbers 
of CD8+ and CD4+ T-cells per 1000 leukocytes in FNAB and peripheral blood samples obtained during IFN-α therapy of patients 
2 and 3 (CD4 data were not obtained at weeks 0 and 2 in these patients).
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ABSTRACT
Background/Aim: To determine whether NK-cells and CD8+ T-lymphocytes contribute to HBV 
clearance during antiviral therapy, we performed a longitudinal analysis of intrahepatic immune 
cells during interferon-α therapy of chronic HBV patients using the FNAB technique. 
Methods: Twenty chronic HBeAg+ patients were treated with pegylated a-interferon 
combined with lamivudine or placebo for 52 weeks. FNAB and blood specimens were obtained 
at week 0, 2, 8 and 52. CD56+ cells, CD8+ T-lymphocytes, interferon gamma (IFNg) and granzyme 
B (GrB) were immunocytochemically quantified.
Results: The relative numbers of CD56+ cells and CD8+ T-lymphocytes were significantly 
higher in FNAB compared to blood at all time-points. About 55% of CD8+ T-lymphocytes in 
FNAB expressed GrB and about 9% IFNg. Responders (n=9) exhibited a significant increase in 
intrahepatic CD8+, CD8+GrB+, and CD8+IFNg+ T-lymphocytes and a decrease in intrahepatic 
CD56+ cells during the first weeks of therapy. In non-responders (n=11) no changes in CD8+ 
T-lymphocytes and an increase in intrahepatic CD56+ cells were observed during therapy. 
Conclusion: The intrahepatic CD8+ T-lymphocyte, but not the NK/NKT-cell response, is 
important for HBV clearance during interferon-α therapy, and the antiviral effect may be 
mediated by both cytolytic and non-cytolytic mechanisms. 
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INTRODUCTION
Hepatitis B virus (HBV) infection is a common disease in humans. It is estimated that more than 
a third of the world’s population has been infected and that about 350 million persons are 
persistent carriers of HBV [1]. Chronic hepatitis B may progress to cirrhosis, liver failure and 
hepatocellular carcinoma [2]. The pathogenetic mechanisms responsible for acute and chronic 
hepatitis B have only partly been clarified. Several studies have shown that the CD4+ and CD8+ 
T-lymphocyte responses to HBV antigens in peripheral blood are strong and multispecific 
in patients with acute hepatitis B [3-4], whereas these responses are weak or even absent in 
chronically infected patients [5-6]. Animal studies demonstrated that CD8+ T-lymphocytes are 
the main effector cells responsible for viral clearance during acute infection [7]. Experiments with 
HBV transgenic mice have shown that, in addition to causing viral hepatitis, HBV-specific CD8+ 
T-lymphocytes can inhibit viral replication by a non-cytolytic mechanism, mediated primarily 
by IFNγ synthesis [8]. Acute HBV infections in chimpanzees [9] and humans [4] revealed that 
non-cytolytic inhibition of viral replication also contributes to viral clearance during natural 
infections. 
Antiviral therapy with interferon-α (IFNα) can induce sustained response rates in between 25 
to 40 percent of chronic hepatitis B patients [10-13]. However, it remains unknown why only a 
part of the chronic HBV patients respond to IFNα therapy. No difference between responders 
and non-responders to IFNα therapy was observed in the HBV specific CD4+ T-lymphocyte 
response in the circulation [14]. During lamivudine therapy, frequencies of HBV-specific CD4+ 
and CD8+ T-lymphocytes rise transiently both in responders and non-responders to therapy 
[15]. 
The frequencies of HBV specific CD8+ T-lymphocytes in the circulation of chronically infected 
patients are very low. However, much higher numbers have been found in liver biopsies of 
patients with persistent infection, especially in patients with low viral load [16]. This suggests that 
intrahepatic CD8+ T-lymphocytes may contribute to control of HBV-replication in chronically 
infected patients. Frequent monitoring of the intrahepatic immune response in chronic HBV 
patients during antiviral therapy may clarify the intrahepatic cellular mechanisms involved in 
therapy-induced clearance. The core-needle biopsy is not suited for this purpose due to its risk 
of complications and pain. In contrast, the cytological fine-needle aspiration biopsy (FNAB) 
procedure represents a safe and atraumatic alternative. This technique was originally developed 
for the diagnosis of acute rejection after kidney- and liver transplantation [17-19]. Recently, we 
found that this technique is suited for the detection of intrahepatic cellular immune responses 
in patients with chronic viral hepatitis [20, 21]. 
The aim of the present study was to establish which type of intrahepatic cellular immune 
response contributes to the clearance of HBV during therapy with pegylated IFNα therapy in 
chronically infected patients. For this purpose we performed multiple FNABs during the course 
of therapy, and assessed whether alterations in intrahepatic CD56+ NK and NKT-cells, and in 
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CD8+ T-lymphocytes containing the cytotoxic protease granzyme B or the antiviral cytokine 
IFNg, were related to viral clearance.
PATIENTS AND METHODS
Patients 
Twenty HBeAg-positive chronic hepatitis B patients (fourteen men and six females) were 
included in this study. The study was a site-specific ancillary study of a global randomized 
controlled trial [22]. Only patients from our liver unit in Rotterdam were enrolled. The Medical 
Ethical Committee of the Erasmus MC approved the study and written informed consent was 
obtained from each patient who entered the study.
Patients with a co-infection of hepatitis C, hepatitis D and patients with a pre-core mutant 
in the HBV genome were excluded. The patients were randomized to receive either pegylated 
a-interferon 2b (Peg-IFNα; 100 mg sc per week) and lamivudine (100mg po per day) or Peg-IFNα 
and placebo, for a period of 52 weeks. After 32 weeks the dose of Peg-IFNα was reduced to 50 
mg per week. The criteria for treatment response in this study were HBeAg seroconversion (loss 
of serum HBeAg) and serum HBV DNA below 1.0 E5 genome equivalents per mL at the end of 
therapy. All other patients were defined as non-responders.
Fine needle aspiration biopsy procedure
In order to study the intrahepatic immune response we performed FNAB at the start of therapy 
and at weeks 2, 8 and 52 (end of therapy). Week 2 and 8 were chosen because IFN-induced 
immune reactivity, as indicated by flares, occurs most frequently during the first 12 weeks of 
therapy [23, 24]. In addition, FNABs were performed during all ALT-flares (ALT above 10 times 
upper limit of normal). The FNABs were performed using a 25 Gauge needle (diameter 0.5 
mm), as described in reference 21. In addition to the FNAB, peripheral blood (PB) was obtained 
by a venepuncture. Cytospin slides were made from the FNAB and blood specimens. One 
cytospins slide of each FNAB-specimen was stained according to the May-Grünwald-Giemsa 
procedure, and used to examine it’s content of hepatocytes. The FNABs were considered to be 
representative if the aspirate contained at least 7 hepatocytes per 100 inflammatory leucocytes 
according to a May-Grünwald- Giemsa stain [19, 25]. The other slides were stored at –20°C for 
immunocytochemistry.
Virological assessments
HBsAg, HBeAg, anti-HBe, anti-HCV and anti-HDV were quantitatively determined by IMX (Abbot 
Laboratories, North Chicago, IL). For the quantitative determination of HBV-DNA an in-house 
TaqMan assay was used. This assay allowed an accurate determination down to 373 geq/ml. 
The assay was calibrated using EUROHEP standards [26, 27]. Analysis of pre-core mutants 
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was performed by an ABI PRISM 3100 genetic analyzer with a Big Dye Terminator v3.0 Cycle 
Sequencing kit (both from Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
Immunocytochemistry
Cytospin specimens of FNAB and peripheral blood were immunocytochemically double-stained 
with CD8 MoAb (CD8-FITC, clone DK25, DAKO, Glostrup, Denmark) and anti-granzyme B (GrB) 
MoAb (clone B7, kindly provided by professor C.E. Hack, CLB, Amsterdam, the Netherlands), or 
anti-IFNg MoAb (clone MD-2, U-Cytech, Utrecht, the Netherlands). Additionally, cytospins were 
single-stained for CD8+ T-lymphocytes (CD8, clone MEM-31, Monosan, Uden, The Netherlands), 
or NK/NKT cells (CD56, clone N901, Beckman Coulter, Hialeah, FL). Cytospin slides were fixed 
in 4% paraformaldehyde in phosphate-buffered saline (pH 7.3). For detection of intracellular 
IFNg, the cells were permeabilized with 0.1% saponine (Merck, Darmstadt, Germany) in Tris-
buffered saline pH 7.4 (TBS) for 15’ at room temperature, and saponine was added in all further 
incubation steps. Endogenous peroxidase activity was reduced by incubating the slides with 
citric acid phosphate (pH 5.8) supplemented with 0.05% hydrogen peroxide (Fluka Chemie, 
Buchs, Switzerland) and 0.1% sodium azide, and non-specific antibody binding was reduced by 
preincubation with TBS supplemented with 10% normal rabbit serum and 10% normal human 
plasma. Subsequently, sections were incubated with anti-GrB or anti-IFNg MoAb overnight. For 
detection of IFNg, endogenous biotin was blocked using the biotin-blocking system from DAKO, 
after which the slides were incubated with biotinylated rabbit anti-mouse immunoglobulins 
(RAM-bio, DAKO) followed by alkaline phosphatase (AP)-conjugated streptavidine (DAKO). 
GrB was detected with rabbit anti-mouse immunoglobulins (DAKO) and AP-anti-AP complex 
(APAAP, Serotec, Oxford, UK) [28]. Thereafter, the slides were consecutively incubated with 10% 
mouse serum (DAKO), with FITC-conjugated CD8 MoAb, and with peroxidase (PO)-conjugated 
rabbit anti-FITC immunoglobulins (DAKO). Binding of CD8 or CD56 MoAb in single-stains 
was detected with rabbit anti-mouse immunoglobulins and APAAP. Visualization of AP was 
performed by incubation in Fast Blue salt / naphtol AS-BI phosphate solution supplemented 
with levamisole (all from Sigma-Aldrich Chemie, Steinheim, Germany), giving a blue precipitate. 
Revelation of PO was performed with 3-amino-9-ethylcarbazole (AEC) giving a red precipitate. 
The optimal dilution of the anti-IFNg MoAb was established by titration on cytospins slides 
of peripheral blood mononuclear cells either or not activated by PMA and ionomycin in the 
presence of Brefeldin. The concentration giving maximal staining of stimulated cells and no 
staining of non-stimulated cells was used.
Quantification and statistical analysis
The cytospin slides of FNAB and PB specimens were examined microscopically at a 
magnification of 400x, and single CD8+ T-lymphocytes, CD8+GrB+, CD8+IFNg+, and CD56+ 
cells were quantified. The total number of leucocytes was assessed by counting the leucocytes 
in 6 microscopic fields of 400 × magnification, and multiplying the mean number per high-
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power fields with 104 (i.e. the total number of high-power fields in one cytospin). Countings 
were performed by one single investigator (T.J.T), who was blinded for response and treatment 
regimen of the patients. For analysis, CD8+, CD8+GrB+, CD8+IFNg+, and CD56+ cells were 
expressed per 1000 leucocytes. Mean numbers of CD8+ T-lymphocytes were calculated 
from the numbers obtained in three different slides stained for CD8 (i.e. the double-stains of 
CD8+GrB+, CD8+IFNg+ and the single-stain for CD8). When the intervariabilty exceeded 20% 
of the mean margin, recounts were done. Data of groups of patients are expressed as mean 
± SEM, unless otherwise indicated. Differences between responders and nonresponders, and 
differences between types of therapy were analyzed by the Mann-Whitney U test. Differences 
Table 1. Baseline characteristics of study patients
Characteristic (n=20) n (%)
Age (years) * 33 (19-57)
Male 14 (70)
Ethnicicty
 White
 Asian
 Other 
11 (55)
 8 (40)
 1  (5)
Route of transmission
 Perinatal
 Sexual
 Parenteral
 Unknown 
7 (35)
5 (25)
1  (5)
7 (35)
HBV DNA (geq/mL) * 1.5 E9 (1.6 E8- 9.1 E9)
ALT (IU/L) * 132 (47-394
Cirrhosis 3 (15)
Previous IFNα treatment 2 (10)
HBV: hepatitis B virus; ALT: alanine aminotransferase;  IFN:  interferon
*Median (range)
A B
Figure 1. Immunocytochemical double-stains of CD8 and GrB (A) (× 1000) and of CD8 and IFNg (B) (× 600) on FNAB cytospins. 
Single CD8+ T-lymphocytes are red/orange, and double stained CD8+ T-lymphocytes have an additional blue stain in the 
cytoplasm. 
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between paired samples were investigated by the Wilcoxon signed-rank test. A p-value of < 
0.05 was considered statistically significant.
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Figure 2. The numbers of CD8+ T-lymphocytes (A) and CD56+ cells (B) per 1000 leucocytes in FNAB versus peripheral blood. 
The relative numbers of CD8+ T-lymphocytes and CD56+ cells in FNAB were elevated compared to blood at each timepoint.
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RESULTS
Patient characteristics
Patient characteristics at baseline are shown in table 1. Eleven patients (55%) were randomized 
to Peg-IFNα plus lamivudine and 9 patients (45%) to Peg-IFNα plus placebo. All included patients 
completed the entire period of therapy. From all scheduled time-points FNABs were obtained 
successfully. A total of 5 flares were detected. In four of these 5 flares patients consented to 
undergo a FNAB. No complications or pain were observed during or after FNAB.
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Figure 3. Granzyme B and IFNg-expression in CD8+ T-lymphocytes in FNAB (A) and in peripheral blood (B). Depicted are the 
proportions of CD8+ T-lymphocytes expressing GrB or IFNg.
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CD8+ T-lymphocytes and NK/NKT-cells during therapy
Figure 1 shows immunocytochemical stains of FNAB cytospin slides for CD8 (red) and GrB (blue) 
(A), and for CD8 (red) and IFNg (blue) (B).
The proportions of CD8+ T-lymphocytes within the leucocytes were significantly elevated 
in the FNAB compared with PB at all time points (28 ± 1.8 vs. 16 ± 1.5, p=0.02) (figure 2A). 
Compared to baseline, a small increase in the relative numbers of CD8+ T-lymphocytes was 
observed in FNAB, but not in PB, at week 8 of therapy; however this difference just failed to 
reach statistical significance (week 0 vs. week 8: FNAB 25.8 ± 2.2 vs. 32.9 ± 2.7, p=0.08). As is 
shown in figure 3, both in FNAB and PB large proportions of CD8+ T-lymphocytes expressed 
GrB; these proportions tended to be higher in FNAB (median 55%, range 46% to 61%) than in 
PB (median 44%, range 38% to 47%, FNAB vs. PB; p=0.11). Much smaller proportions of CD8+ T-
lymphocytes expressed IFNg; also this proportion tended to higher in FNAB (median 9%, range 
7% to 12%) than in PB (median 5%, range 3% to 7%, FNAB vs. PB; p=0.14).
Both in FNAB and in PB the proportions of CD8+ T-lymphocytes expressing GrB or IFNg 
showed no statistical difference between different time-points of therapy. Similar to CD8+ 
T-lymphocytes, the relative numbers of CD56+ NK/NKT-cells were significantly higher in FNAB 
than in blood at all time point (7.0 ± 0.3 vs. 1.2 ± 0.2, p=0.03) (figure 2B). No differences were 
observed between the two therapy regimens regarding relative numbers of CD8+, CD8+GrB+, 
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Figure 4. Relative numbers of CD8+, CD8+GrB+ and CD8+IFNg+ T-cells in FNAB during a hepatitis flare in the patient with 
HBsAg seroconversion.
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CD8+IFNg+ T-lymphocytes, or CD56+ NK/NKT-cells during therapy (data not shown). Therefore 
the treatment groups were combined for further analysis. 
CD8+ T-lymphocytes in ALT-flares during therapy 
In all four patients who exhibited an exacerbation of inflammatory activity (ALT-flare) during 
therapy the relative numbers of CD8+ T-lymphocytes were elevated during the flare as 
Table 2. Baseline characteristics of responders versus nonresponders
Characteristic responders (n=9)
n (%)
non-responders (n=11)
n (%)
Age * 36 (19-45) 31 (21-57)
Male 7 (78) 7 (64)
Asians 4 (44) 4 (36)
HBV DNA (geq/mL) * 2.0 E9 (2.3 E8 - 9.1 E9) 1.2 E9 (1.6 E8 - 5.7 E9)
ALT (IU/L) * 164 (109-236) 86 (47-394)
Cirrhosis 3 (33) 0
Previous IFNα treatment 0 2 (18)
HBV: hepatitis B virus; ALT: alanine aminotransferase; IFN: interferon
* Median (range)
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Figure 5. The course of the relative numbers of total CD8+ T-lymphocytes, CD8+GrB+ T-lymphocytes and CD8+IFNg+ 
T-lymphocytes before, during and at the end of therapy in FNAB of responders (right panels) and non-responders (left panels). 
The values during therapy which are depicted are the peak value observed either at week 2 or week 8 of therapy. Means are 
depicted with bars. (* = baseline vs. peak: p <0.05) 
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compared to baseline (baseline vs. flare: 26.1 ± 3.8 vs. 44.4 ± 10.2, p=0.06). Both the numbers of 
CD8+GrB+ T-lymphocytes (baseline vs. flare: 16.5 ± 7.1 vs. 27.8 ± 6.8, p=0.07) and the number of 
CD8+IFNg+ T-lymphocytes (baseline vs. flare: 2.0 ±1.9 vs. 4.6 ± 2.3, p=0.06) showed an increase 
during the flares. No elevations of CD8+ T-lymphocytes in blood were detected during flares 
(data not shown). One patient exhibiting a flare became HBsAg-negative and produced anti-
HBs. This patient had the most vigorous CD8+ T-lymphocyte response (figure 4).
Clinical features in relation to response to therapy
Response to treatment was observed in 9 of the 20 patients (45%). Three of 9 (33%) patients 
treated with Peg-IFNα plus placebo responded to the therapy and 6 of 11 (55%) treated with 
combination therapy. One patient treated with combination therapy became negative for HBsAg 
(5%). Differences in pre-treatment characteristics between responders and non-responders are 
shown in table 2. The pre-treatment serum ALT was higher in the response group (p=0.05). Pre-
treatment HBV-DNA did not differ between responders and non-responders.
CD8+ T-lymphocytes in relation to response
During treatment responders exhibited a significant increase of total CD8+ T-lymphocytes in 
FNAB (baseline vs. peak 20.2 ± 2.2 vs. 36.2 ± 2.1, p=0.008), which was not observed in non-
responders (baseline vs. peak 28.4 ± 2.2 vs. 30.0 ± 2.6, p=0.64) (figure 5). During this increase 
of CD8+ T-lymphocytes in responders both CD8+GrB+ T-lymphocytes (baseline vs. peak 12.1 
± 2.1 vs. 23.3 ± 3.6, p=0.008) and of CD8+IFNg+ T-lymphocytes (baseline vs. peak 1.2 ± 0.6 vs. 
3.4 ± 0.7, p=0.07) were significantly elevated. In non-responders no increases of CD8+GrB+- 
(baseline vs. peak 15.4 ± 1.7 vs. 16.1 ± 2.1, p=0.93) and or CD8+IFNg+ T-lymphocytes (baseline 
vs. peak 2.8 ± 0.72 vs. 2.5 ± 0.54, p=0.96) were observed during therapy.
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Figure 6. Course of CD56+ cells before, during and at the end of therapy in FNAB of responders (right panel) and non-
responders (left panel). The values during therapy which are depicted are the values corresponding with the peak values of 
CD8+T-lymphocytes observed either at week 2 or week 8 of therapy. Means are depicted with bars. (* : baseline vs. peak: p 
<0.05).
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NK cell response in relation to response
The pre-treatment numbers of NK/NKT-cells in FNAB were significantly higher in responders 
compared to non-responders (9.7 ± 1.5 vs. 3.6 ± 0.9, p=0.004). During treatment, responders 
showed a decrease of NK/NKT-cells in FNAB (baseline vs. peak 9.7 ± 1.5 vs. 5.5 ± 2.8; p=0.02). In 
contrast, non-responders exhibited an increase of NK/NKT-cells in FNAB (baseline vs. peak 3.6 ± 
0.9 vs. 9.5 ± 2.3; p=0.003) (Figure 6).
DISCUSSION
This study is the first description of the longitudinal course of the intrahepatic cellular 
immune response during anti-viral therapy with IFNα of patients with chronic HBV-infection. 
We demonstrate that the FNAB-technique enables sequential monitoring of the intrahepatic 
inflammatory response during antiviral therapy. Two results show that the leukocytes in FNAB 
were indeed derived from the liver: First, by the higher relative numbers of CD8+ T-lymphocytes 
and CD56+ cells in FNAB-specimens compared to PB, which is in accordance with the high 
proportions of these cells among liver lymphocytes [29]. Secondly, the elevations of these 
immune cells in FNAB, but not in PB during hepatitis flares. 
Using this technique, we observed that the response to antiviral therapy with a Peg-IFNα-
based regimen was associated with significant increases of CD8+, CD8+GrB+, and CD8+IFNg+ 
T-lymphocytes, but not of CD56+ cells, in the liver. These results provide the first in vivo evidence 
that intrahepatic CD8+ T-lymphocyte reactivity is vital for successful antiviral therapy of chronic 
hepatitis B patients, and that both cytotoxic activity and secretion of antiviral cytokines are 
important for therapy-induced viral elimination. 
Published studies in patients with chronic HBV treated with IFNα monotherapy [14], lamivudine 
[15], or with combination therapy IFNα and lamivudine [30] all show that antiviral therapy 
enhances the frequencies of HBV-specific T-lymphocytes in the circulation. However, in these 
studies no differences in peripheral T-lymphocyte responses were found between responders 
and non-responders to therapy. The only immunological differences between responders and 
non-responders to anti-viral therapy in these studies were higher peaks in serum levels of IL-12 
and Th-1 cytokines in responders [30]. In accordance with this study, Cooksley et al recently 
reported in an abstract a stronger increase in the ratio of IFN-γ/IL-10 producing HBV-specific 
CD4+ T-cells producing in peripheral blood in responders compared to non-responders during 
therapy with adefovir dipivoxil [31]. Although we did not study IL-12 production and T-helper 
activity in our study, the increase of intrahepatic CD8+ T-lymphocytes, and especially of IFNg-
producing CD8+ T-lymphocytes, during therapy in the responders could be the result of IL-12 
promoting T-helper type 1 and CD8+ T-lymphocyte differentiation.
In our study, the total CD8+ T-lymphocyte elevations correlated with increases of the serum 
ALT flares (data not shown). This may be due to the intrahepatic accumulations of CD8+ T-
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lymphocytes containing GrB, which is a major effector molecule in the cytolytic elimination of 
HBV-infected hepatocytes [32]. In addition to the increase in CD8+ T-lymphocytes expressing 
GrB, response to treatment was also associated with an elevation of CD8+ T-lymphocytes 
expressing IFNg. This suggests that not only cytolytic, but also non-cytolytic mechanisms are 
involved in therapy-induced viral clearance of chronic HBV infection. 
Although we did not investigate whether the intrahepatic CD8+ T-lymphocytes were HBV-
specific, it is generally acknowledged that a proportion of the CD8+ T-lymphocytes present in 
the HBV-infected liver are HBV-specific, and that also bystander CD8+ T-lymphocytes contribute 
to the clearance of HBV [33]. A recent study showed that hepatocellular injury was associated 
with total numbers of intrahepatic CD8+ T-lymphocytes but not with HBV-specific CD8+ T-
lymphocytes [16]. 
The liver contains many NK and NKT-cells [29]. NK cells are believed to play an important 
role in the host defense in the earliest course of HBV infection [34], and increased numbers 
of circulating NK-cells have been observed immediately after HBV-infection [4]. Interestingly, 
in responders we observed higher relative numbers of CD56+ cells in pre-treatment FNAB 
as compared to non-responders. Since liver NK/NKT-cells are thought to be able to recruit T-
cells to the liver [29], the enhanced numbers in responders may have been responsible for 
the intrahepatic accumulation of CD8+ T-lymphocytes during therapy. After starting anti-viral 
therapy the numbers of CD56+ cells increased in non-responders, while they decreased in 
responders, suggesting that with or without lamivudine IFNα therapy stimulates the NK cell 
response in non-responders, while in responders the CD8+ T-lymphocyte response inhibits NK 
cell activation [35]. 
In conclusion, responders to Peg-IFNα-based antiviral therapy are characterized by a 
prominent intrahepatic CD8+ T-lymphocyte response. Elevations of both GrB+ and IFNg+ 
CD8+ T-lymphocytes indicate that cytolytic and noncytolytic mechanisms contribute to viral 
elimination.
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ABSTRACT
Infection of the liver with hepatitis C virus causes compartmentalization of CD8+ cytotoxic T-cells 
to the site of disease. These cells are thought to be involved in viral clearance during interferon 
therapy. The repetitive analysis of the intrahepatic immune response is hampered by the 
difficulty to obtain the intrahepatic T-cells. The fine needle aspiration biopsy (FNAB) technique 
was evaluated for its use to obtain liver-derived CD8+ T-cells in a minimally invasive way. In 
26 chronic HCV-patients who were evaluated for Peg-interferon and ribavirin combination 
therapy, pre-treatment FNABs and peripheral blood specimens were obtained simultaneously 
with liver tissue biopsies, and CD3+ and CD8+ T-cells were quantified by immunocytochemistry. 
The CD8+/CD3+ ratio was significantly higher in the FNABs than in peripheral blood (p<0.01), 
and similar to those in portal areas in the tissue biopsies. A significant correlation was observed 
between numbers of CD3+CD8+ T-lymphocytes in the FNABs and the numbers of CD8+ cells 
in the lobular fields or in the portal tracts of the liver tissue biopsies, but not with CD3+CD8+ 
T-lymphocytes in peripheral blood. Finally, the ratio of CD8+/CD3+ T-lymphocytes in FNABs was 
significantly higher in those patients who responded rapidly to therapy as compared to slow 
responders at 4 weeks of treatment (p=0.02). These findings demonstrate that the intrahepatic 
T-cell composition is reflected in FNABs, and that the FNAB-technique can be used for predicting 
early virological response to therapy of patients chronically infected with HCV.
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INTRODUCTION
In chronic hepatitis C infection, virus-specific T-cells are predominantly found in the liver and are 
almost absent in peripheral blood [1-2]. Intrahepatic localization of CD8+ hepatitis C virus (HCV) 
specific cytotoxic T-cells is thought to be crucial to control acute hepatitis C infection [3] and 
also augment inhibition of viral replication and clearance of infected hepatocytes when chronic 
hepatitis C patients are treated with interferon-α and ribavirin [4-6]. Both total as well as virus-
specific intrahepatic CD8+ T-cell numbers in pretreatment liver tissue biopsies as determined by 
respectively quantitative immunohistochemistry [7] or tested in vitro against target cells [4] are 
associated with virological response to interferon-α therapy. To study intrahepatic T-cell kinetics 
during acute or therapy of chronic infection, the cellular immune status in the liver should be 
monitored on a repetitive basis. The liver tissue biopsy technique is the golden standard for 
obtaining liver tissue. Unfortunately, the biopsy procedure is accompanied with considerable 
patient discomfort. Therefore we investigated the feasibility of a less invasive and traumatic 
fine-needle aspiration biopsy (FNAB) technique as a tool for monitoring the cellular immune 
status in the liver during chronic HCV-infection. Since the early eighties, the FNAB has been 
used for monitoring rejection activity after liver transplantation [8-9]. The FNAB is performed 
with a 25 Gauge needle (diameter 0.5mm) and therefore hardly traumatic. Our aim was to 
investigate whether intrahepatic T-cells as determined by quantitative immunohistochemistry 
(CD3+ and CD8+ cells) in liver tissue biopsies are reflected in FNABs, and whether intrahepatic 
T-cells assessed by FNAB could be used to predict response to interferon-α therapy.
METHODS
Patients
The study group consisted of patients from a single hospital, who were screened for participation 
in a multicenter clinical study in which the efficacy of treatment with Peg-interferon-α2a 180mcg 
per week (Pegasys, Roche, Basel, Switzerland) in combination with 1000-1200mg ribavirin 
(Copegus, Roche) was evaluated. A liver biopsy was part of the evaluation. Standard inclusion 
and exclusion criteria were used. In brief, all patients were interferon-naive, anti-HCV antibody 
positive and had detectable HCV RNA by PCR and elevated serum alanine aminotransferase 
levels (>30 U/l) for at least 6 months on at least two occasions. Patients with decompensated 
liver disease, co-infection with hepatitis B or human immunodeficiency virus, alcohol abuse 
or any other relevant comborbidity were excluded. Within two months after the liver biopsy, 
treatment was started when indicated according to the current treatment consensus [10]. The 
study was in accordance with the Helsinki Declaration of 1975 and approved by the in-house 
medical-ethical committee. All patients gave written informed consent for participation.
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Fine-needle aspiration and liver tissue biopsies 
Pre-treatment two FNABs were obtained. The full details of this procedure are described 
elsewhere [11-12]. Briefly, a mandarin containing 25-gauge needle (diameter 0.5 mm) is 
punctured in the 8th or 9th right intercostal space. After removal of the mandarin, liver cells are 
aspirated by negative pressure into a syringe filled with culture medium. Blood was collected in 
4 mL EDTA plasma tubes (Vacutainer Systems, Plymouth, England). FNABs and blood cells were 
centrifuged on to glass slides using a cytocentrifuge. One cytospin preparation of each specimen 
was stained according to the May-Grünwald-Giemsa procedure. FNABs were considered to be 
representative if the aspirate contained at least seven hepatocytes per 100 leukocytes. If both 
FNABs were representative, the specimen with the highest hepatocyte/leukocyte ratio was 
used in the study.
Directly after the FNAB procedure, a liver tissue biopsy was obtained percutaneously with 
a 14 Gauge Tru-cut needle. The liver specimen was fixed in phosphate-buffered formalin and 
embedded in paraffin. 
Immunocytochemistry fine-needle aspiration biopsies
CD3+ and CD8+ cells present on cytospin slides were visualized by an immunocytological 
double stain technique. The slides were fixed in 4% paraformaldehyde in phosphate-buffered 
saline pH 7.3. Subsequently, endogenous peroxidase was blocked by incubation with citric 
acid buffer pH 5.8 supplemented with 0.03% hydrogen peroxide containing 0.2% (w/v) sodium 
azide for 15 seconds. To reduce aspecific antibody binding, slides were incubated with TBS 
supplemented with 10% normal rabbit serum (Life Technologies, Inc, Gaithersburg, USA) and 
10% normal human plasma (CLB). Subsequentially, the slides were incubated overnight at 4°C 
with CD8 mAb (clone C8/144B, DAKO, Glostrup, Denmark). Detection of primary antibody was 
performed with rabbit-anti-mouse immunoglobulins (RAM, DAKO) for one hour followed by 
alkaline-phosphatase-anti-alkaline phosphatase complex (APAAP, Serotec, Oxford, UK). 
At the end of day 2, the slides were incubated overnight with the second primary mAb CD3-
FITC (clone UCHT1, Immunotech, Marseille, France) at 4°C. At day 3, one hour incubation of 
rabbit-anti FITC-HRP (DAKO) was used to detect CD3. Visualization was performed by incubation 
of the slides firstly in Fast Blue salt / naphtol AS-BI followed by 3-amino-9-ethylcarbazole (AEC). 
Slides were counterstained with methylgreen 1% for 10 seconds and mounted in glycerol. 
Negative controls were either performed by replacement of the primary mAb by an isotype 
matched control mAb or by leaving out the primary antibody. 
Immunohistochemistry liver tissue biopsies 
The distribution of CD3+ and CD8+ cells in the liver was visualized in consecutive sections of 
formalin-fixed, paraffin-embedded liver specimens. The liver sections were firstly deparaffinized 
with xylene (Lab Scan Ltd, Dublin, Ireland) and ethanol (Merck, Darmstadt, Germany). Thereafter 
antigen retrieval was performed by a 15 minutes incubation at 99°C in citrate buffer (pH 6.0) 
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under intermittent microwave exposure. Overnight, the paraffin slides were incubated with 
CD3mAb (clone F7.2.38, DAKO) and CD8mAb (clone C8/14415, DAKO) at 4°C. Slides were washed 
with Tris-buffered saline (TBS) pH 7.3 supplemented with 0.1% Tween-20. CD3 expression 
was demonstrated by a goat anti-mouse Ig conjugated to a peroxidase labeled polymer (En 
Vision HRP system, DAKO) and CD8 antigen was detected with the RAM-APAAP procedure. 
Histochemical revelation was performed by incubation with diaminobenzidine (DAB) or Fast 
Blue salt / naphtol AS-BI phosphate. Negative controls were performed by replacement of the 
primary mAb by an isotype-matched control mAb. Slides were counterstained in case of DAB 
staining with Mayer’s solution (Merck) or in case of Fast Blue staining with nuclear Fast Red 
(Fluka Chemie, Buchs, Switserland)
Quantification of Immunohisto- and Immunocytochemistry positive cells
Two investigators independently examined and counted CD3+ and CD8+ cells in all consecutive 
liver tissue biopsy slides, and CD3+CD8+ and CD3+CD8- cells in FNAB and peripheral blood 
cytospin preparations microscopically at a magnification of 400x. FNAB cytospin preparations 
and tissue biopsy sections were examined independently and in separate sessions. The 
investigators were blinded to the virological and clinical biochemical conditions of the patients. 
In every paraffin biopsy slide 8 microscopic fields within the liver lobuli were randomly selected 
to count CD3+ or CD8+ T-lymphocytes. In addition at least 3 portal tracts were counted.
Since the numbers of leukocytes on individual cytospin preparations may vary, the numbers 
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Figure 2. The median CD8+/CD3+ ratio in peripheral blood, FNABs, portal tract and lobular fields. The upper and lower limits 
of the boxes and the middle line across the boxes indicate the 75th and 25th percentiles and the median (the 50th percentile), 
respectively. The length of the box is thus the interquartile range; the box represents 50% of the data. The upper and lower 
horizontal bars indicate the 90th and 10th percentiles, respectively.
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Figure 3. Variations in numbers of CD8+ T-lymphocytes in the liver tissue biopsies were reflected in the FNAB.
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of positive cells counted were normalized to the number of leukocytes. For that purpose, in 
every FNAB cytospin preparation, 6 microscopic fields were randomly selected to count the 
number of leukocytes. The count was multiplied with 104 (total number of high power fields in 
a cytopsin slide) to obtain the total number of leukocytes per cytospin slide. For analysis, the 
numbers of positive cells were expressed per 1000 leukocytes.
Virological assessments
A quantitative HCV RNA assay was performed to assess viremia (Cobas Amplicor HCV test, 
Roche Diagnostics, Almere, The Netherlands) within one week before or after the liver biopsy. 
In addition these tests were performed at the start of treatment and at 4 and 12 weeks during 
treatment.
Statistical analysis
Data are expressed as mean ± standard deviation, unless otherwise indicated. Pearson’s 
correlation coefficients (r) were used to investigate the correlation between liver, peripheral 
blood and FNAB cell counts. Mann-Whitney tests were performed to investigate differences 
in CD3+/CD8+ ratios between FNAB, peripheral blood and liver tissue biopsies, and between 
treatment response groups. P-values (p) of < 0.05 (two sided) were considered to be statistically 
significant.
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Figure 4. In FNABs a significantly higher median CD8+/CD3+ T-lymphocyte ratio was found in “rapid responders” than in “slow 
responders” at 4 weeks of treatment (p=0.02)(A). At 12 weeks the CD8+/CD3+ T-lymphocyte ratio was lower in patients who 
did not have a 2-log drop with borderline significance (B). For explanation on boxes and lines see figure 2.
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RESULTS
Patients
Twenty-six patients with chronic hepatitis C who underwent a FNAB and a liver tissue biopsy in 
the evaluation for the necessity of antiviral treatment were included in this study. According to 
the most recent treatment consensus [10] therapy was indicated and sequentially started in 23 
patients. There was no indication for treatment in 2 patients, 1 patient was lost prior to therapy 
for further follow-up.
Relation between T-cells in liver FNAB, liver tissue biopsy and peripheral blood
CD8+ and CD3+ T-cells were immunocytochemically detected in FNABs, liver tissue biopsies, 
and peripheral blood specimens (Figure 1). In peripheral blood, about forty percent of the CD3+ 
T-cells were cytotoxic T-cells bearing the CD8 marker. In contrast in the liver, both in the portal 
tracts as well as intralobular, the CD8+/CD3+ ratio’s were significantly higher (both p<0.01; 
figure 2).
FNABs are cytological aspirates and will therefore contain liver-derived as well as blood-
derived leukocytes. To investigate whether the leukocytes in FNABs reflect intrahepatic 
inflammatory cells, we first compared the CD8+/CD3+ ratios found in FNAB, liver tissue biopsies, 
and blood. The CD8+/CD3+ ratio in the FNAB was significantly higher than that in peripheral 
blood (p<0.01), significantly lower than that in the lobular fields (p<0.01), but not different from 
that in portal tracts of the liver tissue biopsies (p=0.46), indicating that T-lymphocytes in FNAB 
originate primarily from the liver (Figure 2). The difference in CD8+/CD3+ between lobular fields 
and
FNAB may be due to the fact that in the liver the majority of both the CD8+ and CD3+ cells 
were present in the portal tracts (Figure 1). Next, we investigated whether variations in numbers 
of CD8+ T-lymphocytes in the liver were reflected in the FNAB. Significant correlations between 
the numbers of CD8+ cells in the lobular fields (r=0.52, p=0.02; figure 3a) or in the portal tracts 
(r=0.58, p=0.01; figure 3b) with the numbers of CD8+CD3+ T-lymphocytes in the FNAB (expressed 
as number per thousand leukocytes) were found. CD3+CD8+ T-lymphocytes in the FNAB did not 
correlate with CD3+CD8+ T-lymphocytes fromperipheral blood (r=0.37, p=0.11; figure 3c).
The numbers of CD3+ T-lymphocytes in the FNAB were also correlated with CD3+ T-cells in 
the portal tracts (r=0.47, p=0.04), but in addition these were weakly associated with those in 
lobular fields (r=0.40, p=0.08) and peripheral blood (r=0.38, p=0.06), indicating that CD3+ T-
lymphocytes in FNAB originate both from liver and blood.
T-cells in pretreatment FNAB in relation to response 
T-cell parameters in FNAB, liver tissue biopsy and peripheral blood as well as treatment data 
such as HCV RNA levels at baseline and at 4 and 12 weeks of treatment and were available in 
20 out of 23 treated patients. In order to investigate differences between treatment response 
Monitoring intrahepatic CD8+ T-cells in chronic HCV infection 95
groups we divided the patients on treatment into two groups according to the decline in HCV 
RNA at 4 and 12 weeks of therapy. The average decline in HCV RNA within the first month of 
treatment was 2.7-log (range: 0.45-5.27). Patients who had a serum HCV RNA decline of less 
than 2.7-log within this period were considered “slow responders” (n=7) and those with a 
decline of more than 2.7-log as “rapid responders” (n=13). The relative numbers of CD8+ T-cells 
were not associated to response (p=0.94), but the ratio of CD8+/CD3+ T-lymphocytes in FNABs 
was significantly higher in responders than in non-responders (p=0.02; figure 4a). At 12 weeks 
of therapy 4 patients did not have at least a 2-log drop of HCV RNA. All 4 were “slow responders” 
at week 4. In these patients the CD8+/CD3+ T-lymphocytes ratio in FNABs was lower compared 
to the group with more then 2-log decline, although with borderline significance (p=0.06; 
figure 4b).
DISCUSSION
In the present study we investigated whether the minimal invasive fine needle aspiration biopsy 
(FNAB) technique could be used as a tool to monitor CD8+ T-lymphocytes in the liver during 
chronic HCV-infection. Comparison of the ratio’s and numbers of CD8+ and CD3+ T-cells in 
simultaneously obtained FNABs, liver tissue biopsies and peripheral blood specimens showed 
that CD8+ T-cells in FNABs were primarily liver-derived. Since, in contrast to circulating T-cells, 
the majority of intrahepatic T-cells are CD8+ T-cells [13-14], first the CD8+/CD3+ ratio’s in the 
three sources were compared. In the FNABs these were similar to those in portal tract, where 
the majority of the intrahepatic CD8+ T-cells reside, but different from that in the blood samples. 
Second, the relative numbers of CD3+CD8+ T-cells in the FNABs correlated significantly with 
the absolute CD8+ T-cell numbers in the lobular fields and the portal tracts of simultaneously 
obtained liver tissue biopsies, while there was no correlation with numbers in peripheral blood. 
On the other hand, variations in numbers of CD3+ T-lymphocytes in the FNABs were associated 
with variations in both peripheral blood and liver tissue biopsies, indicating that CD3+ cells in 
the FNABs originated from the liver and blood. Recently we found that numbers of CD8+ T-
cells in portal tracts of pre-treatment liver tissue biopsies were associated to the occurrence of 
response of HCV-infection on interferon-α therapy [7]. To investigate whether quantification of 
T-cells in FNABs showed association with early virological response during therapy, the patients 
were divided into two response groups according to their individual decline in HCV RNA within 
the first 4 treatment weeks. We choose the average decline of HCV-RNA within the first month 
as value to divide the patients into “rapid” and “slow” responders. According to this limit, a 
significantly higher FNAB CD8+/CD3+ T-lymphocyte ratio was found in “rapid responders” than 
in “slow responders”.
For 12 weeks of therapy, a drop in HCV RNA of at least 2-log recently proved to be essential 
for obtaining a sustained virological response recently [15]. Dividing our patients according to 
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this limit, a borderline significant lower CD8+/CD3+ T-lymphocyte ratio was found in patients 
who did not have at least a 2-log drop of HCV RNA as compared to the other patients. Therefore, 
whether the CD8/CD3 ratio in pretreatment FNAB is predictive for long-term virological 
response to therapy needs to be investigated in a larger patient population.
It is not allowed to compare the present finding directly to our previous finding on the 
association between the numbers of CD8+ T-cells in pre-treatment liver biopsies and response 
to anti-HCV therapy [7], since absolute numbers of cells cannot be measured in FNABS and the 
therapies in both studies are different. In the previous study the patients were treated with 
interferon-α and in the present study with Peg-interferon. The determining role of the immune 
system in obtaining a sustained response is probably much smaller in Peg-interferon therapy 
because of the long lasting and constant antiviral pressure and the relatively high dose when 
compared to 3 MU t.i.w of conventional interferon-α therapy.
In conclusion, we demonstrated that differences in numbers of intrahepatic CD8+ T-cells 
during chronic HCV-infection are reflected in FNABs, and that there is an association between 
the composition of the T-cell population contained in pre-treatment FNABs and early response 
to subsequent anti-viral therapy. We therefore postulate that the FNAB-technique can be used 
as a tool for monitoring the cellular immune status in the liver during chronic HCV-infection on 
a frequent basis.
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ABSTRACT
Chronic carriers of hepatitis B virus (HBV) or hepatitis C virus (HCV) have impaired T-cell responses 
against these viruses. We hypothesized that this immunological deficit may be due to impaired 
presentation of viral antigens by liver-derived dendritic cells (DC) to T-cells in the hepatic 
lymph nodes (LN). To investigate whether the composition of the DC-population in hepatic LN 
is affected in these patients, we compared by quantitative immunohistochemistry the numbers 
of immature Langerhans-type myeloid DC (MDC), mature MDC, plasmacytoid DC (PDC), and 
IFN-α-producing cells in the paracortex of hepatic LN obtained during liver transplantation 
from chronic HBV-patients (n=8), chronic HCV-patients (n=5), patients with liver inflammation 
due to cholestatic liver diseases (n=10), and organ donors with non-inflamed livers (n=10). 
Hepatic LN from patients with chronic HBV- or HCV-infection contained significantly less mature 
MDC, but similar numbers of immature Langerhans-type MDC, PDC and IFN-α producing cells 
compared to hepatic LN from patients with cholestatic liver diseases. Hepatic LN from organ 
donors contained strongly variable numbers of all three DC-types. In conclusion, hepatic LN of 
patients with persistent HBV- or HCV-infection have reduced numbers of mature MDC in their 
T-cell areas. This may be one cause of the impaired anti-viral T-cell response in these patients.
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INTRODUCTION
Many individuals infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) are unable 
to clear these viruses and develop a chronic carrier state. Effective control of these viruses 
during acute self-limiting infections is associated with vigorous and multi-specific antiviral 
T-helper (Th) and cytotoxic T-lymphocyte (CTL) responses. The virus-specific Th lymphocytes 
found during self-limiting infections are predominantly of the T-helper 1 type (Th1), producing 
cytokines which activate the cellular arm of the immune system. In contrast, in chronic carriers 
of these viruses, virus-specific T-cell responses are weak, and Th cells are often characterized 
by a type 2 cytokine response (recently reviewed in [1] and [2]). It is at present unclear why 
chronically infected patients are unable to mount adequate antiviral T-cell responses. 
T-cell respones are initiated by antigen-presenting cells (APC) in secondary lymphoid tissues, 
especially in the lymph nodes (LN) to which the lymph of the infected tissue is draining. The 
most potent APC are myeloid dendritic cells (MDC). These DC are, in contrast to other APC, 
capable of activating naïve T-cells. MDC reside as immature sentenile cells in non-lymphoid 
tissues, specialized in recognition and uptake of pathogens. After antigen uptake MDC’s migrate 
to the regional LN, and, dependent on the type of stimuli they have received, maturate to APC 
with strong T-cell stimulatory capacity [3], or remain in a immature state capable of inducing 
T-cell tolerance [4, 5]. The second main DC-type are the plasmacytoid DC (PDC), which are able 
to produce high amounts of IFN-α upon stimulation by several viruses [6, 7]. This cytokine has 
pronounced direct anti-viral effects [8]. Upon activation, precursor-PDC differentiate into APC, 
which are, by producing IFN-α, able to drive the differentiation of naive T-helper cells into the 
Th1 type direction [9, 10]. 
There are indications that the weak T-cell response during chronic HBV- and HCV-infections 
might be due to reduced numbers and impaired function of MDC. MDC cultured in vitro from 
monocytes of patients with chronic HCV- or HBV-infection were found to have a lower capacity 
to stimulate proliferation of allogeneic T-cells and a decreased capacity to produce the Th1-
driving cytokine IL-12 compared to monocyte-derived MDC from healthy people [11-15]. In 
addition, patients with chronic HBV- or HCV-infection have lower numbers of circulating 
precursor-MDC compared to healthy individuals [14, 16]. However, the anatomical location 
where T-cell responses to these viruses are elicited is not the blood circulation, but the hepatic 
LN. Indeed, recently HBV-specific T-cells capable of reacting to viral antigenic peptides have 
been detected in hepatic LN from patients with chronic HBV-infection [17]. 
To start elucidating whether DC in hepatic LN of patients with chronic HBV- and HCV-infection 
are affected, we compared numbers of MDC, PDC, and IFN-α-producing cells in the T-cell areas 
of hepatic LN from patients with chronic HBV- or HCV-infection, inflammatory liver diseases due 
to a non-viral etiology, and of organ donors with non-inflamed livers.
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MATERIAL AND METHODS
Patients and lymph nodes
During liver transplantations, liver lymph-draining LN were obtained along the hepatoduodenal 
ligament [18] of patients with chronic HBV-infection (n=8), chronic HCV-infection (n=5), primary 
sclerosing cholangitis (PSC; n=5), or primary biliary cirrhosis (PBC; n=5) as indications for liver 
transplantation. In addition hepatic LN were obtained from cadaveric donor-livers (n=10). 
The LN were transported in University of Wisconsin solution to the laboratory and frozen in 
isopentane cooled in liquid nitrogen and stored at -80°C. The Medical Ethical Committee of the 
Erasmus Medical Center approved the study protocol.
Detection of HBV DNA and HCV RNA
Serum HBV DNA and HCV RNA were quantitatively measured by real-time PCR-based assays 
(detection limits: HBV DNA 1 × 103 geq/ml; HCV RNA 100 geq/ml; both manufactured by Roche 
Diagnostics, Almere, The Netherlands).
Immunohistochemistry
To visualize DCs in the paracortex of LN, cryostat sections were double-stained for DC and 
T-cells. At three planes of each LN, consecutive 5 μm cryostat sections were cut. These were 
fixed in 4% paraformaldehyde (10 min), after which endogenous peroxidase was blocked by 
incubation in citric acid/phosphate buffer-solution (pH=5.8) supplemented with 0.05% H2O2 
and 0.2% NaN3 (15 min, 20°C). Aspecific antibody binding was reduced by pre-incubation in 
Tris-Buffered Saline (TBS, pH=7.4) supplemented with 10% Normal Rabbit Serum (NRS) and 
Table 1. Patient and donor characteristics
HBV
(n=8)
HCV
(n=5)
cholestatic
disease
(5 PBC, 5 PSC)
donors
(n=10)
p-
Value
gender (m/f ) 7/1 3/2 5/5 5/5 0.322
age1 (years) 51 (31-59) 57 (44-60) 47 (37-65) 53 (25-64) 0.773
Child-Pugh (A/B/C) 0/1/7 1/2/2 2/5/3 na 0.132
Pre-transplant/donation ALT 
(IU/ml)1
62 (29-590) 50 (35-332) 67 (23-131) … 0.953,4
HBV-DNA/HCV-RNA (geq/ml)
median
range
6.104
<1.103 - 6.107
9.105
7.103 - 6.106
na na na
Hepatocellular Carcinoma 4/8 2/5 0/10 0/10 na
HBeAg+; treated with lamivudine 4/8 na na na na
1median (range)
2Fisher’s exact test
3Kruskal Wallis test
4p-value for the 3 patient groups
na = not applicable
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10% Normal Human Serum (NHS). Primary mAb were applied in optimal concentrations in TBS 
(pH 7.4) supplemented with 1% NHS for 18 h at 4°C. The mAb used were: anti-DC-LAMP (CD208; 
clone 104.G4 [19]), anti-Langerin (CD207; clone DCGM4 [20]), which were both generous gifts 
from Prof. S. Lebecque, Schering Plough Corporation, Dardilly, France, CD123 (Becton and 
Dickinson, Heidelberg, Germany), or isotype-matched control mAb (Dako, Glostrup, Denmark). 
Binding of anti-DC-LAMP and CD123 mAb was detected by incubation with Rabbit-anti-Mouse 
antibodies (Dako) diluted in TBS (pH 7.4) followed by Alkaline-Phosphatase-Anti-Alkaline 
Phosphatase antibody complex (APAAP, Serotec, UK). Anti-langerin was detected by biotinylated 
Rabbit-anti-Mouse antibodies and followed by Streptavidin-Alkaline Phosphatase (AP) (Dako). 
In this procedure, slides were blocked for endogenous biotin with DAKO Biotin Blocking System 
before applying the secondary antibody. Subsequently, all sections were incubated with 10% 
normal mouse serum (Dako, 30 min, 20°C) and subsequently with CD3-FITC (Beckman Coulter 
Immunotech, Marseille, France; 1h, 20°C), followed by Rabbit-anti-FITC-Peroxidase (PO) (Dako). 
To visualize IFN-α producing cells, PFA-fixed sections were incubated with anti-IFN-α mAb 
(UCytec, Utrecht, The Netherlands), followed by biotinylated Rabbit-anti-Mouse antibodies and 
A B
C D
Figure 1. Cryosections of hepatic LN from patients with chronic HBV-infection (A), chronic HCV-infection (B), and PBC (C), and 
from an organ donor (D) immunohistochemically double-stained for T-cells (CD3) in red and for mature MDC (anti-DC-Lamp) 
in blue. The red-coloured areas represent the paracortex. Non-coloured areas are B-cell follicles or medulla. Note that HEVs are 
colourless too.
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Alkaline Phosphatase-conjugated ABC-complex (DAKO). Alkaline phosphatase was visualized 
by Fast Blue/ASBI-phosphate substrate (blue) and PO with Amino-Ethyl-Carbazole (AEC; red). 
Immunohistochemical stainings with anti-IFN-α mAb were counterstained with Nuclear Fast 
Red. Optimal dilutions of primary mAb were established in preliminary experiments by titration 
on human tonsil or skin cryo-sections. Stains were only examined when control stains with 
isotype-matched mAb were negative.
Quantification of DC and IFN-α-producing cells
On each plane of the LN, numbers of DC in the paracortex, which was visualized by the red 
CD3-staining, were counted by two independent observers in six microscopic fields with a 
Figure 3. Immunohistochemical staining of IFN-α in a hepatic LN of a PSC-patient.
�
�
��
��
��
��
��
��
��
� � � � � �
��
�
��
��
��
���
��
��
��
��
�
��
��
��
��
��
��
��
��
��
��
��
��
��
�
��
��
���
�
��
��
��
��
��
��
��
��
���������� �������������������
Figure 4. Numbers of IFN-α+ cells in T-cell areas of hepatic LN from patients with inflamed livers due to chronic HBV-infection, 
chronic HCV-infection, auto-immune cholestatic diseases (PBC or PSC), and from organ donors with a non-inflamed liver. 
Numbers of postive cells were counted per microscopic field of 200 times magnification. Each point represents one LN. Lines 
indicate median values for each group.
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magnification of 630 times. Only brightly coloured cells were counted. For each LN, means 
were calculated from the numbers of DC counted in 18 microscopic fields distributed over the 
three sections by the two observers. Numbers of IFN-α-producing cells were counted in two 
sections of each LN. In each section four randomly selected microscopic fields of 200 times 
magnification were counted by two observers, and the mean of these counts were calculated. 
Statistical analysis: Differences in continuous variables between the four study groups was 
tested by the Kruskal Wallis test for independent samples, and differences in discontinuous 
variables by the Fisher’s exact test. Differences between pairs of groups were tested by the 
Mann-Whitney U test.
RESULTS
Patient characteristics
For this study hepatic LN were collected during liver transplantation procedures from patients 
with chronic HBV- or HCV-infection, and as control groups, from patients with auto-immune 
cholestatic diseases, and from liver-donors, i.e. individuals with non-inflamed livers. Patient- 
and donor characteristics are summarized in Table 1.
The groups did not differ in gender or age. All three patient groups had moderately enhanced 
serum ALT levels, indicating ongoing liver damage at the time of procurement of the LN, while 
the organ donors had normal ALT levels. The majority of the patients had decompensated liver 
cirrhosis, as indicated by the Child-Pugh scores. The Child-Pugh scores tended to be higher in the 
HBV-group as compared to the patients with HCV or cholestatic diseases, but this difference did 
not reach statistical significancy. Four out of eight HBV-patients had antibodies against HBeAg, 
but all had active viral replication (HBV-DNA: 5.104 - 6.107 geq/ml) on the day of transplantation. 
The other four HBV-patients were HBeAg+, and had been treated for at least 2 months before 
transplantation with lamivudine. Nevertheless, in three of them HBV-DNA was still detectable 
in serum on the day of transplantation (4.103 - 6.104 geq/ml). The five patients undergoing liver 
transplantation for chronic HCV-infection had not been treated for HCV for at least 16 months 
before transplantation, and all had active viral replication. The group of patients with auto-
immune cholestatic diseases consisted of five patients with PBC and five with PSC. 
Comparison of numbers of DC in hepatic LN from patients with chronic HBV- or HCV-infection, patients 
with autoimmune liver diseases, and organ donors
Figure 1 shows cryosections of hepatic LN from patients with chronic HBV- (A), or HCV-infection 
(B), PBC (C), and an organ donor (D) immunohistochemically double-stained for T-cells (CD3) in 
red and for mature MDC (anti-DC-Lamp) in blue. The DC-Lamp+-cells are visible as blue cells in 
red-coloured T-cell areas, i.e. the paracortex. Likewise, Langerhans-type immature myeloid DC 
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were detected in the paracortex of the LN by staining with anti-Langerin mAb, and PDC with 
CD123 mAb (not shown). 
The densities of the different DC-types in hepatic LN of the HBeAg+ HBV-patients, which 
had been treated with lamuvidine before transplantation, were similar to those in LN of the 
HBeAg- patients which had not been treated for HBV. Therefore, these LN were combined into 
one group for analysis. Figure 2A shows that the densities of immature Langerhans-type MDC 
in hepatic LN did not differ between the groups. However, as shown in Figure 2B, the median 
density of mature MDC (DC-Lamp+ cells) in the paracortex of LN from chronic HBV-patients was 
about one quarter lower compared to that in LN from patients with liver inflammation due to 
cholestatic diseases (p=0.02). 
Moreover, despite of the limited number of LN from chronic HCV-patients, also in these LN a 
nearly significantly lower density of mature MDC was observed in comparison with LN from PBC 
and PSC patients (p=0.06). When the data from the patients with HBV- and HCV-infection were 
taken together, the median density of mature MDC in the paracortex of their hepatic LN was 
22% lower compared to that in LN from PBC and PSC patients (p=0.007). Due to considerable 
variation in the densities of mature MDC in LN from organ donors, mature MDC-densities in 
hepatic LN of the patient groups did not differ significantly from those in the LN of the organ 
donors (combined HBV- and HCV-patients versus organ donors: p = 0.26; cholestatic liver 
diseases versus organ donors: p = 0.56). 
In a previous study (Tanis et al, submitted) we found that hepatic LN, both from non-inflamed 
livers and from patients with auto-immune cholestatic diseases, have about four times less PDC 
in their paracortex as compared to muscle-and skin-lymph draining LN. Figure 2C shows that 
chronic HBV-infection does not result in an increase in CD123+ PDC-numbers in hepatic LN, 
while PDC-numbers tended to be further decreased in hepatic LN from chronic HCV-patients 
(HCV-group versus HBV-group: p = 0.09).
Comparison of numbers of IFN-α producing cells in hepatic LN from patients with chronic HBV- or HCV-
infection, patients with autoimmune liver diseases, and organ donors
The main source of IFN-α in secondory lymphoid organs in vivo are PDC [9]. Immunohisto-
chemical staining of LN-sections with an anti-IFN-α mAb showed that IFN-α-producing cells 
were mainly situated in the T-cell areas (Figure 3). 
Microscopic quantification revealed that the numbers of IFN-α producing cells varied 
considerable within the study groups, but did not differ significantly between hepatic LN of the 
different study groups (Figure 4).
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DISCUSSION
Inflammatary components, like necrotic cells [21] and cytokines [22], stimulate the maturation 
of MDC. Therefore, we estimated that hepatic LN from patients with liver inflammation due to 
PBC or PSC would contain higher numbers of mature MDC compared to those of organ donors 
with non-inflamed livers. This was, however, not the case. Hepatic LN from organ donors showed 
a large variation in mature MDC-numbers. This variation may be due to the presence or absence 
of factors, like endotoxins absorbed from the gut [23], or cytokines released in the early phase 
of brain death [24], which stimulate the maturation and migration of liver MDC to the hepatic 
LN in organ donors. Indeed, in some cadaveric liver transplants Kupffer cells are activated and 
in others not [25]. Much less varation in DC-numbers was observed in the LN from the patient 
groups with inflamed livers, where continuous stimulation of hepatic DC may be assumed. 
The present study shows that hepatic LN from patients with liver inflammation due to chronic 
HBV- or HCV-infection contained significantly less mature MDC in their T-cell areas as compared 
to hepatic LN from patients with liver inflammation due to PBC or PSC. Mature MDC are the most 
potent APC known. Moreover, hepatic LN are probably the primary sites where MDC present 
viral peptides derived from the infected hepatocytes to T-cells. We therefore propose that the 
reduced numbers of mature MDC in these LN may be one of the causes of the impaired anti-
viral Th and CTL-responses, which are characteristic for patients with persistent HBV- or HCV-
infection. Whether MDC in hepatic LN of chronic HBV- or HCV-patients are also functionally 
impaired, will be investigated in future studies in which MDC will be isolated from hepatic LN. 
The presence of lower numbers of mature MDC in the hepatic LN of chronic HBV- or HCV-
patients might be caused by an impairment in MDC-maturation in the liver of these patients. 
This possibility is suggested by the reduced maturation of monocyte-derived MDC from such 
patients observed in vitro [11-15]. If impaired maturation had occurred in vivo, increased 
numbers of immature MDC would be expected to be present in the hepatic LN of chronic 
HBV- and HCV-patients. However, we observed similar numbers of immature Langerin+ MDC 
in hepatic LN of all patient groups and in the control group of organ donors. Langerin is a 
molecule specific for the epithelial immature MDC type, i.e. the Langerhans cell. We suppose 
that the Langerin+ cells in the hepatic LN represent Langerhans cells immigrated from the 
Glisson capsule of the liver, like Langerin+ cells in skin-lymph draining LN are considered to 
represent Langerhans cells immigrated from the skin [26]. At present no specific antibodies 
are available for the interstitial type of immature MDC [27], which is supposed to be present 
in the liver parenchyma. Therefore, in the present immunohistochemical study we could not 
determine whether increased numbers of immature interstitial-type liver MDC were present in 
the hepatic LN from chronic HBV- and HCV-patients. Such analysis can only be done by multi-
parameter flow cytometry of LN cell suspensions. 
The lower numbers of mature MDC in hepatic LN from chronic HBV- and HCV-patients may 
also be due to reduced availability of bone marrow-derived precursor-MDC in these patients. 
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Recently, it has indeed been reported that patients with chronic HBV- and HCV-infection have 
reduced numbers of circulating precursor-MDC in comparison with healthy individuals [14, 
16]. 
PDC are the principal producers of the anti-viral cytokine IFN-α. Moreover, this cytokine can 
direct the differentiation of naïve Th cells into the Th1 direction. However, to influence the 
outcome of the T-helper response, IFN-α must be produced at the site where naïve T-cells are 
activated, i.e. in secondary lymphoid tissue. Several, but not all, viruses are able to induce IFN-α 
production by PDC in vitro [7, 9] and in lymphoid organs in vivo [28]. Here, we found that the 
numbers of IFN-α producing cells, as well as the numbers of PDC, were not increased in the 
hepatic LN of patients with chronic active HBV- or HCV-infection, compared with those from 
PBC- and PSC-patients and those of organ donors. Apparently, HBV- and HCV do not stimulate 
IFN-α production in hepatic LN in vivo in chronically infected patients. Whether this is due to 
inability of these viruses to trigger IFN-α production by PDC, or whether other factors present 
in chronic HBV- or HCV-patients inhibit the production of this cytokine, will be investigated 
in future studies. We have previously shown that hepatic LN contain few PDC compared with 
skin-muscle-lymph draining LN (Tanis et al, submitted). Possibly, the relative shortage of IFN-α 
producing PDC in hepatic LN is another cause of the impaired anti-viral Th and CTL-responses 
in chronic HBV- and HCV-patients. 
In conclusion, this pilot study shows that hepatic LN in patients with persistent HBV- or HCV-
infection have reduced numbers of mature MDC in their T-cell areas compared to hepatic LN of 
patients with liver inflammation due to auto-immune cholestatic diseases, and that the numbers 
of IFN-α producing PDC in hepatic LN are not enhanced during these chronic infections. These 
deficits in the DC-system of hepatic LN may be at least in part responsible for the impaired anti-
viral Th and CTL responses found in these patients. 
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SUMMARY AND CONCLUSIONS
Intrahepatic immune response in chronic hepatitis B infection (chapter 2 and 3)
More than a third of the world’s population has been infected with hepatitis B virus (HBV) and it 
is estimated that there are 350 million persistent carriers of HBV worldwide, 25% of whom have 
active chronic liver disease and cirrhosis, which could progress to hepatocellular carcinoma. 
The annual mortality rate is approximately one million people worldwide, which makes it a 
major global health concern. 
It is not clearly known how an individual develops a chronic hepatitis carrier state; however, 
a defective immune response of the host is thought to play a critical role in the underlying 
pathogenetic mechanism. HBV clearance is associated with co-ordinated activation of both 
the cellular and humoral arms of the adaptive immune response that ultimately control the 
virus. A proper activation of the innate response is necessary for full development of an efficient 
anti-viral adaptive immune response. The earliest responses are non-specific and include type 
I IFN, NK and NK-T cells, non-specific activation of Kupffer cells and proper dendritic cell (DC) 
maturation. In addition of being a first line of defence against the virus, the innate immune 
respons is necessary to deliver the signals to a proper adaptive response. The fundamental step 
of antiviral protective immunity is the elimination of intracellular virus by the cellular response. 
This has long been thought to require the immune destruction of infected hepatocytes by 
cytotoxic T-lymphocytes (CTL). Recent investigations have demonstrated that the cellular 
immune response can also purge HBV from infected hepatocytes without killing the infected 
cells, by secreting of antiviral cytokines (IFN gamma and TNF alpha) that inhibit viral gene 
expression and replication, thereby curing the HBV infection without destruction of the liver. 
CD8+ CTLs are the main immune effector cells in the viral clearance. However, little is known 
about the immune mechanisms which control viral replication during chronic HBV-infection. 
A majority of chronically infected patients survive for several decades. In these patients 
apparently a balance emerges between liver injury and viral replication, indicating a phase 
of relative immune control. In addition to CTLs, cells of the innate immune response, such as 
macrophages, Kupffer cells, natural killer (NK) cells may contribute to control of the virus and 
to tissue injury. Most of the available information is based on studies on anti-viral T-cells in 
the circulation of patients. Since the infection is localized in the liver, we decided to study the 
intrahepatic immune response. 
In chapter 2, we studied the immune balance between HBV and the chronically infected 
host. We performed a cross-sectional study in which we determined the associations between 
numbers of intrahepatic immune cells on the one hand and viral replication and liver damage 
on the other hand in patients with HBeAg+ and HBeAg- chronic HBV-infection. We found 
that low HBV replication and HBeAg negativity were associated with increased numbers of 
intralobular CD8+ T-lymphocytes in liver biopsies. This suggests a prominent role of CTL in 
immune control of viral replication during chronic infection. We did not determine whether 
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these intrahepatic CD8 T-lymphocytes were HBV specific T-cells, but additional investigations 
showed an activated state of these cells, revealed by the presence of intracellular cytotoxic 
granule proteases granzymes A and B. In contrast to patients with fulminant HBV-infection, the 
intrahepatic CD8+ T-lymphocytes in the patients with chronic infection did almost not produce 
antiviral cytokines. The absence of intrahepatic cytokine production may be one of the causes 
of viral persistence in these patients. NK (CD56+) and plasmacytoid dendritic cells (CD123+), 
which are the principal producers of IFNα, were rare in the liver specimens, suggesting a limited 
role in chronic HBV infection. An interesting finding was the Fas-ligand upregulation on Kupffer 
cells in patients with inflammatory liver damage, suggesting a contribution of Kupffer cells to 
virus-induced liver injury. 
In chapter 3, we investigated whether the pre-treatment numbers of intrahepatic CD8+ T-
lymphocytes were related to response to anti-viral therapy in chronic HBV patients. We found 
firstly, that the pretreatment numbers of intrahepatic CD8+ T-cells were higher in responders 
than in nonresponders and, secondly, that the intrahepatic lobular CD8 T-cells decreased 
significantly in responders, but remain unchanged in nonresponders. These findings suggest 
that in responders, CD8+ T-cells infiltrated in the liver favour complete viral elimination during 
antiviral therapy. Further studies must be performed to investigate whether the CD8+ T-cells 
present in the lobular fields at the end of therapy are HBV-specific T-cells, controlling the virus. 
For guidance of antiviral management, our results demonstrate that the pretreatment numbers 
of CD8+ T-lymphocytes may predict response to antiviral therapy. Future studies must indicate 
whether this finding could have clinical implications for antiviral therapy. 
The primary host immune attack against HBV is the cause of the liver injury, mediated by a 
cellular response to small epitopes of HBV proteins, especially HBcAg, presented on the surface 
of the hepatocyte. HLA-class I-restricted CD8+ cells recognize HBV peptide fragments derived 
from intracellular processing and presented on the hepatocyte surface by class I molecules. An 
interesting finding was that cytoplasmic HBcAg expression was significantly associated with 
higher number of intrahepatic CD8+ T-lymphocytes and that they were co-localized in the 
liver. This strongly suggests that these CD8+ T-cells exert antiviral activity at the site of maximal 
replication resulting in a complete disappearance of HBcAg-infected hepatocytes at the end of 
therapy. 
The intrahepatic immune response during treatment of chronic HBV-patients as determined by Fine-
Needle aspiration biopsies (chapter 4 and 5)
The intrahepatic cellular immune response during chronic HBV infection can be monitored 
occasionally, but not frequently with the traditional liver tissue biopsy technique, due to its risks 
and discomfort. Successful therapy for chronic HBV infection consists of immune modulation 
(interferon alpha) or direct inhibition of viral replication with nucleoside analogues. However, 
it is at present unknown why only part of chronic HBV patients responds to these treatments. 
Longitudinal investigations of the intrahepatic immune response during de novo infection or 
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treatment of chronic HBV infection have not been performed yet, because these were hampered 
by the lack of an alternative tool for the liver tissue biopsy. In chapter 4 we introduce the fine-
needle aspiration biopsy (FNAB) as a low-risk and patient-friendly tool for frequent monitoring 
of the intrahepatic immune response during therapy of patients with chronic HBV-infection. 
The FNAB was sensitive and able to measure a significant CD8+ T-lymphocytes elevation in the 
liver during ALT flare-ups in three chronic HBV patients, compared to non-flare episodes during 
antiviral therapy. This elevation was associated in one patient with a sustained seroconversion, 
indicating that the T-lymphocytes collected by the FNAB-technique reflect antiviral immune 
reactivity. 
Subsequently, we used the FNAB to investigate in a large cohort of chronic HBV patients 
which intrahepatic mechanisms of CD8+ T-cells were involved in viral clearance during antiviral 
therapy.
In chapter 5, intrahepatic CD8+ T-cells expressing granzymes and CD8+ T-cells secreting 
IFN gamma, representing the two pathways of anti-viral activity of CTLs were frequently 
determined in FNAB during antiviral therapy. The first conclusion we could draw was that there 
was a significant CD8 T-cell response in the liver, which was absent in peripheral blood during 
antiviral therapy. This supports the notion that the predominant immune response against HBV 
is at the site of replication and not in peripheral blood. Secondly, in responders to antiviral 
therapy, and not in non-responders, a significant elevation of intrahepatic CD8+ T-cells was 
observed during treatment. This treatment response was associated with elevations of CD8 
T-lymphocytes containing granzyme B and CD8 T-lymphocytes expressing IFN gamma during 
antiviral therapy. It remains unclear whether this elevation of CD8+ T-lymphocytes is the result of 
recruitment of activated CD8 T-cells or expansion of locally resting T-cells that have recognized 
viral antigens. The major conclusions from this study was that a prominent intrahepatic CD8+ 
T-cell response was present in responders to antiviral therapy and not in nonresponders and 
that cytolytic and noncytolytic mechanisms were both involved in the response to antiviral 
therapy.
Intrahepatic immune response in relation to treatment of chronic HCV-infection as determined by FNAB 
(chapter 6)
More than seventy percent of adults infected by hepatitis C virus develop a chronic infection. 
Like for HBV-infection, it has been proposed that the ability to mount an efficient cellular 
immune response is the main mechanism responsible for HCV control, whereas a deficient 
immune response leads to chronicity. Based on our experience with the application of FNAB 
in chronic HBV patients, we validated the FNAB for detection of intrahepatic CD8+ T-cells in 
chronic HCV patients by comparison with liver tissue biopsies. Chapter 6 reports that we found 
increased relative numbers of CD8+ T-cells in the FNAB-specimens compared to peripheral 
blood, suggesting an increased activity of CD8+ T-cells at the site of infection. Subsequently, 
we questioned whether we could use this parameter for prediction for response of antiviral 
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therapy with interferon-alpha. In our study, significantly more CD8+CD3+ T-cells were observed 
in pre-treatment FNAB of “rapid responders compared to ‘slow responders” to interferon alpha 
therapy. This suggests a higher absolute number of HCV–specific CD8+ T-cells in the liver and 
prominent role of CD8+ T-cells in the cellular response to HCV in the ‘rapid responders’. 
Crucial role for dendritic cells in viral control in chronic viral hepatitis (chapter 7)
Dendritic cells act as a link between the innate and adaptive immune response. Signals from 
the innate immune system often lead to a proper maturation of DCs, which are critical for 
triggering the antigen-specific immune response. The ability of DCs to induce T-cell responses 
is influenced by their tissue localization and the viral load. Activation of CD8 T-cells in lymph 
nodes draining lymph from the site of infection occurs very rapidly and is mediated by DCs. 
Chronic hepatitis B or hepatitis C patients have impaired T-cell responses against these viruses. 
Given the important role played by DCs in T-cell priming, we raised the hypothesis that this 
immunological deficit may be due to impaired presentation of viral antigens by liver derived 
dendritic cells to T-cells in the hepatic lymph nodes. This may be due to an alteration of the DC 
function and/or maturation induced by the high viral load or even by infection of the DCs by HBV 
or HCV. In chapter 7, we quantified myeloid DC and plasmacytoid DC in immunohistochemical 
stainings of hepatic lymph node sections obtained from liver transplant recipients. The major 
finding in this study was that hepatic lymph nodes from patients with chronic HBV- or HCV 
infection contained significantly less mature myeloid DC, but similar numbers of immature 
myeloid DCs, plasmacytoid DC and IFNα producing cells compared to hepatic lymph nodes of 
patients with liver inflammation due to cholestatic liver diseases. This finding strongly suggests 
that viral chronicity may be associated with reduced numbers of mature myeloid DCs in hepatic 
lymph nodes causing an impaired anti-viral T-cell response and subsequently a deficient 
intrahepatic immune response.
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SAMENVATTING EN CONCLUSIES
De intrahepatische immuun respons bij een chronische hepatitis B infectie (hoofdstuk 2 en 3)
Meer dan een derde van de wereldbevolking is geïnfecteerd met het hepatitis B virus (HBV) 
en wereldwijd zijn er ongeveer 350 miljoen mensen die persisterende dragers van het HBV 
zijn; 25% daarvan hebben een actieve chronische leverziekte en cirrose, die kan leiden tot 
hepatocellulair carcinoma. De jaarlijkse mortaliteit wordt geschat op een miljoen mensen 
wereldwijd, waardoor HBV een mondiaal gezondheidsprobleem is. Het is nog onbekend hoe 
een individu na infectie zich ontwikkelt tot een chronische drager van het HBV; een defect in 
het immuun systeem van de gastheer lijkt een belangrijke rol te spelen in de onderliggende 
pathogenese. Klaring van het HBV is geassocieerd met een gecoördineerde activatie van de 
cellulaire alswel de humorale onderdelen van de specifieke immuun respons dat uiteindelijk 
het virus onder controle houdt. Een juiste activatie van de niet-specifieke immuun respons is 
noodzakelijk voor een volledige ontwikkeling van een efficiënte antivirale specifieke immune 
respons.
De vroege responsen zijn niet-specifiek en bestaan uit secretie van type I IFN, infiltratie 
van Natural Killer (NK) en Natural Killer-T (NK-T) cellen, maturatie van dendritische cellen 
(DC) en activatie van Kupffer cellen. De niet-specifieke immuun respons is het eerste 
verdedigingsmechanisme tegen het virus en is nodig om een effectieve specifieke immuun 
respons in gang te zetten. De essentiële stap van een beschermende antivirale immuun respons 
is de eliminatie van intracellulair virus door de cellulaire respons. Er werd lang aangenomen 
dat dit bereikt werd door vernietiging van geïnfecteerde hepatocyten door cytotoxische T-
lymfocyten (CTL).
Recent onderzoek heeft uitgewezen dat de cellulaire immuun repons het HBV kan 
verwijderen uit geïnfecteerde hepatocyten zonder deze te beschadigen, namelijk door secretie 
van antivirale cytokinen (IFNγ en TNFα) die de virale genexpressie en replicatie inhiberen en 
daarbij de HBV infectie genezen zonder leverschade. CD8+ CTL’s zijn de voornaamste immuun-
effector cellen in deze virale klaring.
De meerderheid van chronisch geïnfecteerde patiënten hebben een overleving van enkele 
tientallen jaren. Er lijkt een balans te ontstaan tussen leverschade en virale replicatie in deze 
patiënten, wat aangeeft dat zij in een fase van relatieve immuun controle van het virus 
verkeren. 
Naast de CTL’s dragen cellen van het niet-specifieke immuunsysteem, zoals macrofagen, 
Kupffer cellen, NK- en NK-T cellen bij aan de controle van het virus en aan veroorzaken 
weefselschade. De meeste beschikbare gegevens betreffende de cellulaire immuun respons 
tegen HBV zijn verkregen door studies van antivirale T-cellen in de circulatie van chronische 
HBV patiënten. Omdat de primaire infectie gelokaliseerd is in de lever zelf, hebben wij besloten 
om de intrahepatische immuun respons te bestuderen.
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In hoofdstuk 2 hebben wij de balans tussen HBV en het immuun systeem van de chronisch 
geïnfecteerde patiënt bestudeerd. Een cross-sectionele immunohistochemische studie 
werd uitgevoerd met lever biopsieën van HBeAg-positieve en negatieve chronische HBV-
patiënten, waarin wij de verbanden hebben bestudeerd tussen de aantallen intrahepatische 
immuun cellen enerzijds en virale replicatie en leverschade anderzijds. Wij vonden dat 
lage HBV replicatie en HBeAg-negativiteit geassocieerd waren met een verhoogd aantal 
intralobulaire CD8+ T-lymfocyten in lever biopten. Dit suggereert een prominente rol van 
CTL’s in de immuun gemedieerde controle van virale replicatie tijdens een chronische infectie. 
Of deze intrahepatische CD8 T-lymfocyten HBV-specifieke T-lymfocyten waren, hebben wij 
niet onderzocht, maar aanvullend onderzoek heeft wel aangetoond dat deze cellen in een 
geactiveerde status waren, weergegeven door de aanwezigheid van intracellulaire cytotoxische 
proteasen Granzym A en B.
In tegenstelling tot patiënten met een fulminante HBV infectie, maakten de intrahepatische 
CD8 T-lymfocyten in de patiënten met chronische infectie geen antivirale cytokines. Afwezigheid 
van intrahepatische cytokine productie kan één van de oorzaken zijn van virale persistentie in 
deze patiënten.
NK (CD56+) en plasmacytoide dendritische cellen (CD123+), de voornaamste producenten 
van IFNα, waren zeldzaam in de lever biopsieën, wat suggereert dat ze een beperkte rol hebben 
in chronische HVB infectie. Een interessante bevinding was de opregulatie van Fas-Ligand op 
Kupffer cellen van patiënten met inflammatoire leverschade. Dit suggereert dat Kupffer cellen 
bijdragen aan de virus geïnduceerde lever schade.
In hoofdstuk 3 hebben wij onderzocht of de aantallen CD8+ T-lymfocyten die voorafgaand aan 
antivirale therapie met IFNα, aanwezig zijn in de lever van chronische HBV-patiënten, gerelateerd 
zijn aan de respons op deze therapie. Wij vonden allereerst, dat in lever biopsieën die genomen 
waren voorafgaand aan de behandeling, de aantallen intrahepatische CD8+ T-lymfocyten 
hoger bij waren responders dan bij nonresponders. Ten tweede, dat de CD8+ T-lymfocyten in 
de lever significant afnamen tijdens de therapie bij responders, maar stabiel bleven in aantal bij 
de nonresponders. De derde interessante bevinding was dat cytoplasmatisch HBcAg-expressie 
in hepatocyten significant was geassocieerd met hogere aantallen intrahepatische CD8+ T-
lymfocyten in de biopsieën. CD8+ T-lymfocyten en cytoplasmatisch HBcAg vertoonden co-
localisatie. Dit suggereert dat deze CD8+ T-lymfocyten hun antivirale activiteit uitoefenen op 
de plaats van maximale virus replicatie, en dat dit resulteert in complete eliminatie van met 
HBV geïnfecteerde hepatocyten aan het einde van therapie.
Deze bevindingen suggereren dat bij responders de voorafgaand aan therapie in de lever 
geïnfiltreerde CD8+ T-lymfocyten complete virale eliminatie begunstigen tijdens antivirale 
therapie. Vervolgstudies moeten uitwijzen of de CD8+ T-lymfocyten die intralobulair aanwezig 
zijn aan het einde van de therapie HBV-specifieke T-lymfocyten zijn die het virus controleren.
Met betrekking tot beleid voor antivirale therapie, laten onze resultaten zien dat aantallen 
intrahepatische CD8+ T-lymfocyten voorspellend zijn voor de kans op respons. 
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De intrahepatische immuun respons bepaald met de Dunne-Naald aspiratie biopsie tijdens behandeling 
van chronische HBV patiënten (hoofdstuk 4 en 5)
De intrahepatische cellulaire immuun respons tijdens chronische HBV infectie kan met de 
traditionele lever biopsie techniek af en toe onderzocht worden, maar niet frequentvanwege 
de risco’s en het ongemak. Succesvolle therapie voor chronische HBV infectie bestaat uit 
immuunmodulatie (interferon alfa) of directe inhibitie van virale replicatie met nucleoside 
analogen. Echter, het is tot op heden niet bekend waarom een deel van de chronische 
HBV patiënten niet respondeert op deze behandelingen. Longitudinaal onderzoek van de 
intrahepatische immuun respons tijdens de novo infectie of behandeling van een chronische 
HBV infectie is tot op heden nog niet uitgevoerd, omdat dit belemmerd werd door de 
afwezigheid van een alternatief voor de leverbiopsie. 
In Hoofdstuk 4 introduceren wij de dunne naald aspiratie biopsie (fine-needle aspiration 
biopsie; FNAB) als een patiënt vriendelijker alternatief voor frequente monitoring van de 
intrahepatische immuun respons tijdens therapie bij patiënten met een chronische HBV 
infectie. Aan deze techniek zijn nagenoeg geen risico’s verbonden. De FNAB-techniek bleek 
sensitief genoeg om een stijging van CD8+ T-lymfocyten in de lever te meten tijdens ALT-
flares in drie chronische HBV patiënten. Bij één patiënt werd tevens een stijging van CD4+ T-
helper lymfocyten in de FNAB waargenomen, die werd gevolgd door een blijvende HBeAg-
seroconversie. Dit betekent dat de T-lymfocyten verkregen door middel van de FNAB-techniek 
antivirale activiteit weergeven tijdens de therapie. 
Vervolgens pasten wij de FNAB-techniek toe in een groot cohort chronische HBV patiënten 
om te onderzoeken welke intrahepatische mechanismen van CD8+ T-lymfocyten betrokken 
zijn bij virale klaring tijdens antivirale therapie. In de studie beschreven in hoofdstuk 5 
werden CD8+ T-lymfocyten met IFNγ en granzymes gekwanficeerd in FNAB die longitudinaal 
tijdens antivirale therapie met IFNα werden genomen. Deze markers representeren de twee 
mechanismen van antivirale activiteit van CTL’s. De eerste conclusie uit deze studie was dat 
er een significante stijging van CD8+ T-lymfocyten was in de lever, maar niet in perifeer bloed 
tijdens antivirale therapie. Dit gegeven ondersteunt het concept dat er een predominant 
immuun respons tegen HBV aanwezig is op de plaats van replicatie en niet in perifeer bloed. 
Ten tweede werd bij responders op antivirale therapie een significante stijging van het aantal 
CD8+ T-lymfocyten waargenomen in de FNAB tijdens behandeling, welke afwezig was bij non-
responders. Deze therapie geïnduceerde respons bestond uit stijgingen van zowel CD8+ T-
lymfocyten die granzyme B bevatten als CD8+ T-lymphocyten die IFNγ tot expressie brachten. 
De voornaamste conclusies van deze studie waren dat er een prominente intrahepatische 
CD8+ T-lymfocyt respons aanwezig was bij responders op antivirale therapie en niet bij non-
responders en dat zowel cytolytische als non-cytolytische mechanismen betrokken zijn bij de 
anti-virale respons tijdens therapie met IFNα.
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De intrahepatische immuun respons bepaald met FNAB in relatie tot behandeling van chronische HCV-
infectie (hoofdstuk 6) 
Meer dan zeventig procent van volwassenen die geïnfecteerd zijn met het hepatitis C virus 
(HCV) ontwikkelt een chronische infectie. Men heeft voorgesteld dat, evenals bij HBV-infectie, 
de opbouw van een efficiënte cellulaire immuun respons het voornaamste mechanisme is voor 
HCV controle en dat een deficiënte immuun respons leidt tot chroniciteit van de infectie. Op 
basis van onze ervaring met het gebruik van de FNAB-techniek bij chronische HBV patiënten, 
hebben wij de FNAB gevalideerd voor het detecteren van intrahepatische CD8+ T-lymfocyten 
bij chronische HCV patiënten, door vergelijking met materiaal verkregen middels een standaard 
lever biopsie.
Hoofdstuk 6 geeft weer dat de relatieve aantallen CD8+ T-lymfocyten in FNAB materiaal van 
patiënten met chronische HCV-infectie significant gecorreleerd waren met de aantallen CD8+ 
T-lymfocyten in lever biopsieën. In de tweede plaats vonden we dat de CD8+/CD3+ T-lymfocyt 
ratio in FNAB gelijk was aan die in portale gebieden van de lever, maar hoger dan in met perifeer 
bloed. Vervolgens hebben wij ons afgevraagd of we deze parameter kon worden gebruikt 
voor predictie van kans op respons op antivirale therapie met interferon alfa. In onze studie 
werd een significant hogere ratio CD8+/CD3+ T-lymfocyten geobserveerd in FNAB genomen 
voorafgaand aan behandeling bij “snelle responders” ten opzichte van “langzame responders” 
op interferon alfa therapie. Dit suggereert een prominente rol van CD8+ T-lymfocyten in de 
door therapie geïnduceerde respons tegen HCV bij “snelle responders”.
Cruciale rol voor dendritische cellen bij virale controle in chronische virale hepatitis (hoofdstuk 7)
Dendritische cellen fungeren als een verbinding tussen de niet-specifieke en specifieke 
immuun respons. Signalen vanuit het niet-specifieke immuun systeem dragen bij aan een 
adequate maturatie van DC’s, die belangrijk is voor het initiëren van de antigeen-specifieke 
immuun respons. De mogelijkheid van DC’s om T-cel responsen te induceren wordt beïnvloed 
door hun weefsel lokalisatie en waarschijnlijk ook door de virale load.
Activatie van CD8+ T-lymfocyten geschiedt in lymfe-drainerende lymfeklieren in de regio van 
infectie door DC’s. Chronische hepatitis B en C patiënten hebben een verzwakte T-cel respons 
tegen deze virussen. Door de belangrijke rol van DC’s in het proces van T-cel priming, vroegen 
we ons af of deze immunologische tekortkoming een gevolg is van een verzwakte presentatie 
van virale antigenen opgenomen door DC’s in de lever aan de T-cellen in de hepatische 
lymfeklieren. Dit kan het gevolg zijn van een verandering in de functie en/of in de maturatie 
van DC’s geïnduceerd door een hoge virale load of zelfs door infectie van de DC’s zelf door HBV 
en HCV. 
In hoofdstuk 7 hebben wij de myeloide en plasmacytoide DC’s gekwantificeerd door 
middel van immunohistochemische kleuringen van hepatische lymfeklieren verkregen van 
levertransplantatie patiënten. De voornaamste bevinding in deze studie was dat hepatische 
lymfeklieren van patiënten met een chronische HBV en HCV infectie significant minder 
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mature myeloide, maar hetzelfde aantal immature myeloide, en plasmacytoide DC’s bevatten 
vergeleken met lymfeklieren van patiënten met inflammatie ten gevolge van cholestatische 
leverziekten. Tevens was het aantal IFNα producerende cellen gelijk. Dit resultaat suggereert 
sterk dat chroniciteit van deze virale infecties het gevolg is van verlaagde aantallen mature 
myeloide DC’s in hepatische lymfeklieren wat een verzwakte antivirale T-cel respons veroorzaakt 
en vervolgens een deficiënte immuun repons in de lever.
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CHAPTER 2
A
B
Figure 2. Liver biopsy sections immunohistochemically stained with CD8 mAb from chronic HBV patient with normal (A) and 
raised ALT (B) (× 400)
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B
Figure 4. Consecutive liver biopsy sections immunohistochemically stained with Fas-L mAb (a) or CD68 mAb (b), showing that 
Fas-L is expressed predominantly on Kupffer cells (× 400)
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CHAPTER 3
A
B
Figure 1. Immuno double-stain of HBcAg and CD8 T-lymphocytes (brown=HBcAg; CD8 T-lymphocytes=blue). Scattered 
nuclear expression of HBcAg and CD8 T-lymphocytes (original magnification × 200) (A). Clustered cytoplasmic expression of 
HBcAg (original magnification × 100) and co-localisation of cytoplasmic HBcAg and CD8 T-lymphocytes (inserted left, original 
magnification × 200) (B).
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CHAPTER 4
A B
Figure 1. A: May-Grünwald-Giemsa-stained cytospin preparation of a FNAB obtained during a hepatitis flare containing many 
lymphocytes. The large cells are hepatocytes. B: Immunocytochemical CD8-stain (red) of a FNAB cytospin preparation obtained 
during a hepatitis flare.
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CHAPTER 5
A B
Figure 1. Immunocytochemical double-stains of CD8 and GrB (A) (× 1000) and of CD8 and IFNg (B) (× 600) on FNAB cytospins. 
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CHAPTER 7
A B
C D
Figure 1. Cryosections of hepatic LN from patients with chronic HBV-infection (A), chronic HCV-infection (B), and PBC (C), and 
from an organ donor (D) immunohistochemically double-stained for T-cells (CD3) in red and for mature MDC (anti-DC-Lamp) 
in blue. The red-coloured areas represent the paracortex. Non-coloured areas are B-cell follicles or medulla. Note that HEVs are 
colourless too.
Figure 3. Immunohistochemical staining of IFN-α in a hepatic LN of a PSC-patient.
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mijn onderzoek, waarvoor dank.
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Het secretariaat van de SLO wil ik bedanken voor alle administratieve handelingen die bij een 
promotieonderzoek horen. Marion dank ik voor alle werkzaamheden in het laatste traject. 
Alle collega’s van het laboratorium MDL dank ik hartelijk voor de jarenlange samenwerking en 
de prettige werksfeer: ik kom terug. 
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ben ik de persoon geworden die ik nu ben. 
Beste Dave en Mathieu, beide aanvankelijk mijn tegenpolen, maar later collega en vriend 
geworden. Bedankt dat jullie mijn paranimfen willen zijn op deze dag. 
Lieve Sahn, met jouw steun en interesse heb ik dit proefschrift afgemaakt. Veel avonden en 
weekenden heb jij met mij doorgebracht achter de PC. Na deze beproeving hoop ik meer tijd 
te hebben om onze toekomstplannen te realiseren. 
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ABBREVIATIONS
ALT alanine aminotransferase
anti-HBe antibody against HBeAg
cccDNA covalently closed circular DNA
CI confidence interval
CTL cytotoxic T lymphocyte
DC dendritic cell
DNA desoxyribonucleic acid
Fas-L Fas-Ligand
FNAB fine needle aspiration biopsy
Geq genome equivalents
HBcAg hepatitis B core antigen 
HBeAg hepatitis B envelop antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HDV hepatitis D virus
HIV human immunodeficiency virus
IFN-α interferon-alpha
IFN-γ interferon-gamma
IL interleukin
IU international units
LN lymph node
mAb mouse antibody 
MDC myeloid dendritic cell
MU mega-units
NK cell natural killer cell
PB peripheral blood
PBC primary biliary cirrhosis
PCR polymerase chain reaction
PDC plasmacytoid dendritic cell
PEG pegylated
PSC primary sclerosing cholangitis
RNA ribonucleic acid
SD standard deviation
SEM standard error of mean 
TNF-α tumor necrosis factor-alpha

